Towards early detection of neurodegenerative diseases: A gut feeling

The gastrointestinal tract communicates with the nervous system through a bidirectional network of signaling pathways called the gut-brain axis, which consists of multiple connections, including the enteric nervous system, the vagus nerve, the immune system, endocrine signals, the microbiota, and its metabolites. Alteration of communications in the gut-brain axis is emerging as an overlooked cause of neuroinflammation. Neuroinflammation is a common feature of the pathogenic mechanisms involved in various neurodegenerative diseases (NDs) that are incurable and debilitating conditions resulting in progressive degeneration and death of neurons, such as in Alzheimer and Parkinson diseases. NDs are a leading cause of global death and disability, and the incidences are expected to increase in the following decades if prevention strategies and successful treatment remain elusive. To date, the etiology of NDs is unclear due to the complexity of the mechanisms of diseases involving genetic and environmental factors, including diet and microbiota. Emerging evidence suggests that changes in diet, alteration of the microbiota, and deregulation of metabolism in the intestinal epithelium influence the inflammatory status of the neurons linked to disease insurgence and progression. This review will describe the leading players of the so-called diet-microbiota-gut-brain (DMGB) axis in the context of NDs. We will report recent findings from studies in model organisms such as rodents and fruit flies that support the role of diets, commensals, and intestinal epithelial functions as an overlooked primary regulator of brain health. We will finish discussing the pivotal role of metabolisms of cellular organelles such as mitochondria and peroxisomes in maintaining the DMGB axis and how alteration of the latter can be used as early disease makers and novel therapeutic targets.

Introduction

Neurodegenerative diseases (NDs) such as Alzheimer disease (AD) and Parkinson disease (PD), are a rising burden to society (Aarli et al., 2006; Feigin et al., 2019; 2020; Kassebaum, 2022). The World Health Organization heeds that the rising incidence of NDs are one of the most significant public health challenges now and in the coming decades (Aarli et al., 2006; Ou et al., 2021), as long as preventative strategies and viable treatments remain elusive (Raz, 2010; Durães et al., 2018). For a detailed clinical review of the epidemiology, we refer the reader to (Erkkinen et al., 2018).

NDs manifest with multiple clinical complications and life quality constraints. They can affect the motor system, causing ataxias (Bologna and Paparella, 2020), and the cognitive system, causing dementias. However, the etiologies of NDs are unclear due to the complex genetic and environmental factors believed to underly the mechanism of disease. Multiple studies now suggest that changes in factors outside the brain, such as diet, gut microbiota (dysbiosis), metabolism, and intestinal inflammation, are linked to the risk and progression of NDs.

For example, consuming ultra-processed food enhances the risk of developing AD (Li et al., 2022), as high-fat diets are linked to the development of chronic metabolic and inflammatory diseases associated with neuroinflammation and reduced cognitive function (Cai, 2013).

The intestinal microbiota composition is sensitive to changes in diet and to the host’s metabolic and inflammatory status. Dysbiosis of commensal populations is linked to metabolic perturbations associated with psychiatric disorders such as autism spectrum disorder (ASD) (Festi et al., 2014; Pulikkan et al., 2019) and NDs such as PD and AD (Cai, 2013; Sampson et al., 2016; Zhang et al., 2018). Additionally, prolonged antibiotic use and high-fat diets are linked to commensal dysbiosis, weak intestinal-barrier function, and dysplasia of the gut epithelium. These changes correlate with elevated local and systemic inflammation and deficiencies of nutrients essential for brain health. This is because the intestinal microbiota supply essential nutrients such as vitamin B or K and their derivatives to nourish the development of the central nervous system (CNS) (Das et al., 2019; Ma et al., 2019). For example, bacterial metabolites such as short-chain fatty acids (SCFAs), including acetic acid, butyric acid, and propionic acid, are integral for learning and memory (Trinder et al., 2017) and reduction in SCFAs is associated with inflammation in Multiple Sclerosis patients and compromised neuronal function in various NDs (Ma et al., 2019).

The intestinal epithelium plays a central role in digestion and nutrient absorption, defense against pathogens, cooperation with beneficial commensals, and production of systemic endocrine signals. Recent work has shown that NDs may be seeded distally in the intestinal epithelium before disease in the brain via the gut-brain axis (Shannon et al., 2012; Sánchez-Ferro et al., 2015; Brudek, 2019; Chen et al., 2019; Challis et al., 2020; Mertsalmi et al., 2020; Castelli et al., 2021). Multiple studies report the accumulation of protein aggregates, hallmark pathologies of NDs such as AD and PD, appearing in enteric neurons or the gastrointestinal epithelium years before detection in the central nervous system (Braak et al., 2003; Hawkes et al., 2010; Devos et al., 2013; Chalazonitis and Rao, 2018; Kowalski and Mulak, 2019).

NDs are also characterized by abnormalities in peroxisomes and mitochondria (Nunomura et al., 2001; Reddy and Beal, 2008; Reddy 2009; Kou et al., 2011; Cipolla and Lodhi, 2017; Aparicio et al., 2022; Fedele et al., 2022; Roczkowsky et al., 2022). These organelles are central to cellular metabolism, redox stress, and immune signaling (Johannsen and Ravussin, 2009; Kou et al., 2011; Di Cara, 2020). In the intestinal epithelium, both organelles also mediate critical interactions with the gut microbial population (Di Cara et al., 2018). Thus, the consequences of aberrant peroxisome or mitochondrial function in the intestinal epithelium might represent hallmark to early onset of NDs.

Together, this evidence supports the idea that interactions between the diet, gut microbiota, and intestinal epithelium shape the lines of communication between the gut and the brain, which can protect or damage brain health (Figure 1). Understanding this communication is a promising area of research to better define the etiologies of NDs.

FIGURE 1

FIGURE 1. Schematic of the diet-microbiota-gut-brain axis in the context of neurodegenerative diseases. The gut, and gut-microbiota are known to secrete protective neurotrophic factors to promote brain health, neuron survival, and plasticity (Left path). If gut metabolism is perturbed, due to altered communication between the gut, and gut-microbiota, both influenced by the diet, these protective factors may not be secreted or function as intended (Right path). Perturbed gut metabolism corresponds to the appearance of neurodegenerative pathologies (Fibrils and plaques), years before appearing in the brain and causing disease. Figure constructed on BioRender.com.

In this review, we discuss current evidence demonstrating that the perturbation of the host intestinal metabolism by genetics, organelle damage, or environmental factors (e.g., dietary changes or antibiotic treatment) affects the diet-microbiota-gut-brain (DMGB) signals that govern brain health representing a significant factor in the onset of NDs. We report experimental evidence demonstrating the links between alteration of the DMGB axis and NDs in studies carried out in Drosophila and murine model organisms. We will describe the elements of the DMGB axis in health and NDs. Finally, we will analyze the open questions in the field and discuss how unraveling the mechanisms of the DMGB axis leads to the prediction of early diagnostic markers for NDs—ultimately aiding in the development of alternative therapies that involve microbial or microbial-host metabolism targeted treatments.

Neurodegenerative diseases

The brain is the central information processor and relay for most higher-order eukaryotes (Thau et al., 2022; Y; Wang et al., 2020). Part of the Central Nervous System (CNS), the brain is interoceptive to distal organs via the Peripheral Nervous System (PNS) to modulate brain-organ communication and tissue homeostasis (Buchanan and Tranel, 2009; Waxenbaum et al., 2022). In addition to direct neuronal impulses mediated by neurotransmitters, other means of crosstalk include humoral/endocrine communication by secretion of molecular agents such as hormones, lipids, and peptides (Castillo-Armengol et al., 2019); these forms of communication are bidirectional (Castillo-Armengol et al., 2019). However, cross-talk efficiency and capacity may diminish with age, as the synthesis of neurotransmitters and signaling molecules are curtailed in the brain and peripheral tissue, leading to tissue-specific/systemic diseases (Venkat et al., 2015; Ali et al., 2018). Emerging literature suggests that distal organ stress, whether metabolic or inflammatory, can impact brain function (Peters, 2006; Atamna et al., 2018).

NDs are defined by severe, progressive, and debilitating cognitive and motor disturbances (Jahn, 2013; Levenson et al., 2014; Muddapu et al., 2020) caused by neuronal death in specific vulnerable brain regions that varies with the disease such as striatal regions in PD, striatal and hippocampal and cortical regions in AD (Muddapu et al., 2020). Despite best efforts to find a cure and alleviate the Global Burden of Disease and financial burdens of NDs (Weintraub and Horn, 2008; Vossius et al., 2011; Wong, 2020; Yang et al., 2020; Ou et al., 2021), the etiologies remain elusive, and research on pathogenesis is still greatly speculative (Durães et al., 2018).

NDs are categorized into two groups; genetic and sporadic (Bekris et al., 2010; Pang et al., 2017). Sporadic NDs, contributing to over 90% of cases, are the most difficult to study because pathogenesis is driven by both spatial and temporal interactions of environmental and genetic factors, which are still largely unclear (Lu and Vogel, 2009; Pang et al., 2017; Muddapu et al., 2020; Hampel et al., 2021). On the contrary, genetic cases are much easier to study. Canonical human-linked alleles of NDs have already been identified and manipulated in many model organisms to mimic and study human disease (i.e., Mus musculus: mouse, and Drosophila melanogaster: fruit fly) (Bekris et al., 2010; Steinkamp et al., 2012). The genetic epidemiological spotlight currently points to genes that encode for proteins prone to, or that facilitate, oligomerization and aggregation (i.e., α-Synuclein and Amyloid precursor protein) or involved in autophagy and mitochondrial metabolic stress (i.e., PINK1, Parkin). The etiology of genetic NDs is also not clear due to the complexity of the mechanisms of diseases that involve both genetic and environmental factors, including diet and microbiota in both hereditary and sporadic forms (Festi et al., 2014; Hakansson, A. and Molin 2011; Hampel et al., 2021; Pang et al., 2017). Advancements in genomics, proteomics, single cell analysis, and metabolomics technology, along with multidisciplinary research approaches, have opened new frontiers in the investigations of the origins and mechanisms of disease especially sporadic NDs (Pang et al., 2017; Zheng and Chen, 2022).

The current use and repurposing of antibiotics and probiotics to treat NDs supports the hypothesis of peripheral origin of these diseases (Durães et al., 2018). This is also supported by the existence of afferent cues derived from the metabolic interactions of the microbiota, dietary factors, and the gut, which have neuroprotective effects on the brain but lead to NDs when perturbed (Brudek, 2019; Chen et al., 2019; Challis et al., 2020; Mertsalmi et al., 2020; Castelli et al., 2021). Therefore, the pathogenesis of NDs may not be confined to the brain but originate from an interorgan-communication network of the DMGB axis. Deciphering the molecular networks of the DMGB axis that distinguish between healthy individuals and patients with specific NDs represents a promising area to define not only the etiology of NDs but also the identification of early disease biomarkers to permit early intervention and prevention of disease progression.

The brain is an immune-privileged organ with a Blood Brain Barrier (BBB), a selectively permeable membrane that prevents drug diffusion into the brain (Daneman and Prat, 2015). For this reason, it is challenging to construct synthetic drugs that can easily cross the BBB to treat NDs within the brain (Pardridge, 2012) with high bioavailability in the brain tissue and without any first-pass effects (Harris et al., 2014). Therefore, alternative treatments that correct metabolic signaling at peripheral sites will alleviate the need for treatment with psychotherapeutics. Targeting the DMGB axis to address the defects that lead to disease in the gut instead of the brain offers alternative treatment options, such as dietary changes, to prevent side effects than current psychotherapeutics may cause (Winiarska-Mieczan et al., 2020). In the following sections, we will report results from studies that support the idea that the onset of NDs, such as AD and PD, begins with disturbances in the DMGB axis and that novel strategies that target this axis can address these devastating disorders.

The gut-brain axis in alzheimer disease

Physiopathology of alzheimer disease

Dementias, such as AD, are the most common types of NDs, with a higher prevalence in females than males (Mielke, 2018; Podcasy and Epperson, 2016; Y; Wang et al., 2020). The hallmark pathologies of AD, identified in both sexes, negatively affect cognition, predominantly long and short-term/working memory, and locomotor behavior (Clancy, 2013; Da Costa et al., 2013; Ju et al., 2013; Levenson, et al., 2014; Raskin et al., 2015; Podcasy and Epperson, 2016). The formation of aggregates of misfolded protein oligomers such as extracellular β-amyloid plaques or intracellular neurofibrillary tangles (NFTs), made of tau microtubule-associated protein (Mohandas et al., 2009; Kou et al., 2011; Hampel et al., 2021; Tracy et al., 2022) are late pathological hallmarks that cause damage to mitochondria and oxidative stress in neurons. Of protein aggregates in neurons and neuronal loss, observed as inclusion bodies that form lesions throughout the tissue (Takatori et a., 2019; Morley et al., 2018; Raskin et al., 2015; Sarantseva et al., 2009; Shadfar et al., 2015). The inclusion bodies spread over time to surrounding neurons through cell-to-cell prion-like propagation (for a detailed review on the cell-to-cell prione propagation, please refer to Hofmann et al., 2013), causing high oxidative stress and widespread inflammation of the brain, ultimately facilitating atrophy of the tissue as the disease progresses (Ashraf et al., 2014).

Evidence of the distal seeding of alzheimer disease caused by Aβ fibrils

The Amyloid Precursor Protein (APP) is one member of a single-pass transmembrane protein family characterized by large extracellular domains. When APP is proteolytically cleaved by β/γ secretases, the product is amyloidogenic ABeta/β-amyloid peptide (Aβ) (Chen et al., 2017). The role of APP and its products is not very clear. The preeminent role of APP in the development of AD depends on the toxicity of the Aβ peptide since the loss of APP function does not seem deleterious. In AD patients, accumulation and aggregation of Aβ peptides forms Aβ fibrils that are acutely toxic to neurons. Aβ fibrils formation toxicity might explain also other pathological aspects of AD including neurofibrillary tangles, inflammation, and oxidative damage. For a detailed review on the pathogenesis of AD we refer the reader to a review by (O'Brien and Wong, 2011).

APP and β/γ secretases are not exclusive to the CNS. Recent studies reported regular APP expression in the Enteric Nervous System (ENS) of mice, suggesting an ENS involvement in AD (Van Ginneken et al., 2011; Semar et al., 2013; Chalazonitis and Rao 2018). The transgenic mice that over express a mutant form of human APP in the ENS are associated with early-onset familial AD, exhibiting an accumulation of Aβ in the enteric neurons leading to a decrease in enteric neuron abundance, dysmotility, and increased vulnerability to inflammation (Chalazonitis and Rao 2018). Preliminary data confirms that changes in location or amount of APP in the ENS correspond to disease expression in transgenic mice carrying APP mutation. APP aggregation in ENS appeared before any disease sign was detectable in the brain. Similarly, Αβ deposits have been observed in the Gastrointestinal (GI) tract of patients that overexpress APP (Semar et al., 2013; Sun et al., 2020). Although the study of the role of Aβ in the gut in the context of AD is still in its infancy, there have been increasing evidence that support a model where Aβ triggers NDs from the gut in the brain (Braak et al., 2003; Chalazonitis and Rao, 2018; Kowalski and Mulak., 2019).

The nature of this distal pathological seeding was hypothesized by Dr. Heiko Braak. His theory was based on observations that the pathogenesis of NDs, in the context of PD, was mediated by α-Synuclein inclusion bodies that develop first in the gut before translocate to the brain via the vagal and motor nerves by an unknown mechanism of gut-brain communication (Braak et al., 2003) (see next section). This hypothesis was then applied to β-amyloid pathogenesis by (Sun et al., 2020). In this study, 2-month-old ICR mice were injected with HiLyte Fluor 555-labelled Aβ42 (the APP isoform most prone to oligomerization) into the stomach and colon and exhibited defects in responsive/exploratory behavioral, short-term and long-term memory cognitive deficits 1-year post-injection. Despite evidence that the labelled Aβ42 monomers did not diffuse through the tissue, Aβ42 remained localized to cholinergic neurons at the injection sites 3 hrs and 3 days post-injection. Further, these mice displayed clear depositions of Aβ plaques throughout the brain, and vagus nerve (DMV), with plaques visible in the hippocampus, cortex, amygdala, and blood vessel walls. Thus, intra-GI administration of Aβ had a direct effect on the neuronal system, with β-amyloid deposits from the gut translocating to the CNS from the ENS via the vagal nerve by an unknown mechanism of gut-brain communication. Although this work hypothesized that a retrograde transport route had caused the presence of Αβ aggregates in the brain of the mice, there remains no direct evidence demonstrating that enteric Αβ seeds can retrogradely invade the CNS to induce AD symptoms. However, it is posited that the enteric Aβ seeds invade the brain and cause dementia by retrograde axonal transport through the vagal nerves and haematogenous routes, as seen in prion pathology (Watts et al., 2014). The enteric Αβ seeds did not seem to affect GI major functions when the animals were analysed at 1-year post-injection and only alteration of spontaneous contractions and neuronal couplings of the jejunum, which did not result in constipation, were observed. A difference in contraction frequency of the GI was detected also in another APP transgenic mouse (Semar et al., 2013). Other interesting metabolic defects such as weight gains were observed in various transgenic models. Weight changes (Wagner et al., 2019) have been associated with dementia in humans and are linked to disease progression (Ikeda et al., 2002). In a similar study (Galloway et al., 2007), identified neuronal tissue death alongside translocation of β-amyloid from the gut of mice.

Systemic oxidative stress as a cause of Aβ protein aggregates in the CNS and pathogenesis

While these murine studies demonstrated that Aβ42 aggregates can form in the GI tract and then enter the brain leading to cerebral amyloidosis and AD-like dementia, other studies showed the existence of a correlation between the amount Aβ42 protein and the extent of oxidative stress and inflammation in the brain of mice and humans (Tamagno et al., 2021). The brain’s vulnerability to oxidative stress is considered a crucial detrimental factor in AD. Aβ induces oxidative stress, and on the other hand oxidative stress can increase Aβ deposition. Notably, while the increase of soluble Aβ42 is correlated to elevated oxidative stress, inflammation, and tissue atrophy of the brain, neither the rate of dementia nor the extent of neurological damage is correlated with the Aβ amyloid. Studies on transgenic mice carrying AD-linked mutations in the gene for APP demonstrated the existence of soluble Aβ oligomers long before the deposition of β-amyloid, further supporting the hypothesis that in particular conditions, an over-production of soluble Aβ aggregates occurs in the human brain even in the absence of plaques. One of the main mechanisms that appears to break this balance is oxidative stress and neuroinflammation (Chang et al., 2014). There is growing consensus that oxidative stress represents a common mechanism that mediates the accumulation and toxicity of Aβ (Saeedi and Rashidy-Pour, 2021). Therefore, oxidative stress can be considered one of the factors responsible for the accumulation of Aβ.

Preliminary evidence from transgenic APP mice and AD human patients indicates that build-up of Aβ in enteric neurons causes inflammation of the gut before any sign of disease is detected in the brain. Enteric inflammation promotes “leaky” guts that release inflammatory mediators/bacteria-derived products into the blood circulation, leading to systemic/neuro-inflammation by weakening the BBB (Chalazonitis and Rao, 2018; Kowalski and Mulak, 2019). For a review of the role of the BBB in neurodegeneration, we refer the readers to (Hussain et al., 2021). Other studies support the theory that oxidative stress and inflammation in the gut may instead trigger β-amyloid aggregation in the brain by means of chronic, low-grade systemic inflammation (Braak et al., 2003). This was proposed from observations that a long period of gradual accumulation of oxidative damage precedes and results in the appearance of clinical and pathological AD symptoms, including Aβ deposition, NFT formation, metabolic dysfunction, and cognitive decline. This suggests that AD begins many years before its symptoms appear, and that antioxidant treatment can be an important therapeutic target to treat the disease (Saeedi and Rashidy-Pour, 2021). Like many neurological disorders, AD is associated with a variety of GI symptoms, raising the possibility that the ENS could also be affected. A clinical report showed that Aβ plaques were found in the submucosa of two AD patients (Joachim et al., 1989). However, with a paucity of evidence and some discordance in the findings, there remains a clear need for further studies of enteric neuronal pathology in AD.

The microbiota as a trigger of amyloid aggregates and neuroinflammation in the pathogenesis of AD

The stimuli that trigger β-amyloid inclusion formation in the gut remain to be elucidated. The gut microbiota is a significant source of amyloids, changes in the microbiota may potentiate disease in the gut. Disruption of the microbiome occurs as a result of pathogenic infection, antibiotic treatment, aging, and local inflammation (Hakansson and Molin, 2011; Rinninella et al., 2019). Certain bacterial species in the gut, such as E. coli, can even produce bacterial amyloids that help the bacteria to form biofilm and survive mechanical and immune stressors (Kowalski and Mulak, 2019). Although bacterial amyloids differ from CNS amyloids in their primary structure, they share similarities in their tertiary structure (Friedland, 2015; Zhao et al., 2015). Shifts in commensal populations that favour species releasing amyloids would increase the concentration of bacterial-derived amyloid proteins in the gut triggering a prion-like cascade of β-amyloid oligomerization/aggregation in the gut (Hetz and Saxena, 2017) or promote cleavage of APP into its Aβ-amyloid peptides (Sarantseva et al., 2009; Bekris et al., 2010; Simon, 2018; Li et al., 2019). A pioneering study of PD carried out by (Chen et al., 2016) demonstrated that rats exposed to amyloid-producing Escherichia coli displayed increased neuronal α--Synuclein deposition in both the gut and brain and enhanced microgliosis and astrogliosis compared to rats exposed to bacteria without the ability to produce amyloids. Moreover, in the brain of animals exposed to amyloid-producing bacteria they measured an increased expression of inflammatory cytokines and reactive oxidative and nitrosative stressors which lead to neuronal and glial cell death (Chen et al., 2016; Li et al., 2016). Thus, bacterial amyloids can act as molecular mimics of prion proteins, eliciting cross-seeding, in which one amyloidogenic protein (bacteria amyloid protein) promotes another (e.g., host proteins) to also adopt a pathogenic β-sheet structure (Lundmark et al., 2005; Zhou et al., 2012).

Therefore, a combination of gut inflammation and dysbiosis is directly associated with gut barrier dysfunction and increased intestinal permeability (“leaky gut”) may contribute to the process of neurodegeneration (Marizzoni et al., 2017; Sochocka et al., 2019). Lipopolysaccharide (LPS) from commensals or pathogenic bacteria leaked from the gut can reach and accumulate in the brain and activate microglia, brain resident immune cells, and elicit inflammatory responses in the brain. LPS has been detected in the hippocampus and neocortex brain lysates from AD patients and has been found to colocalize with Aβ40/42 β-amyloid plaques (Zhao et al., 2017). Interestingly, the plasma concentration of LPS in AD patients is significantly higher than in healthy people (Zhang et al., 2009), and repeated systemic exposure to LPS in mice induced microglial priming and prolonged cytokine production.

Perturbation in microglia activation has been identified as a feature of NDs progression. For full reviews on the topic, we refer the readers to (Hickman et al., 2018) and (Muzio et al., 2021).

Tao-derived aggregates in the gut in the pathology of AD

Tauopathies, are a group of NDs that include a form of AD, which are characterized by abnormal hyperphosphorylation of microtubule-associated protein tau that leads to the formation of NFTs. Similar to β-amyloid pathogenesis of NDs in the brain, tau monomers oligomerize and form aggregates known as NFTs and neuritic plaques, which form inclusion bodies that cause inflammation due to intra/extra-cellular damage in and around neurons (Anwal, 2021; Bălaşa et al., 2020; Takatori et al., 2019). NFTs have been found to accumulate in the gut and to cause gastrointestinal dysfunction such as alteration of gut motility before any clinical symptom is found in the brain (Kametani and Hasegawa, 2018). Moreover, both β-amyloid and also tau tangles/plaques promote local intestinal inflammation and weakening of the gut epithelial barrier (Kowalski and Mulak, 2019). The weakening of the gut epithelial barrier can cause metaflammation (low-grade chronic systemic inflammation) that has been linked to NDs (Komleva et al., 2021; Rydbom et al., 2021). For a review on metaflammation we refer the readers to (Itoh et al., 2022).

Although the mechanisms of DMGB axis pathogenesis in the context of ADs are poorly defined, concurrent evidence shows that the diseases may manifest/originate in the gut before appearing in the brain.

The gut-brain axis in parkinson disease

Physiopathology of parkinson disease

PD has been identified as one of the most rapidly growing NDs in the world (Dorsey et al., 2018) and is more prevalent in males than females (Moisan et al., 2016; Podcasy and Epperson, 2016; Feigin et al., 2019). This disease is primarily defined by progressive loss of motor-function (initiation and coordination) of the brain, along with bradykinesia. These behavioral disturbances are due to atrophy of the substantia nigra (Faustini et al., 2017; Dorsey et al., 2018), an essential medullary brain region that produces and projects dopamine to the limbic system, and higher cortical areas (Mayfeild, 2010). These projections are known as nigrostriatal pathways, activating regions of the brain that control motor-behavior (Zeighami et al., 2015; Faustini et al., 2017; Sonne, et al., 2021). Despite a similar pattern of atrophy in PD brains compared to healthy aging brains, the pathologies of the disease are what exacerbate and accelerate this phenotype (Zeighami et al., 2015). Hallmark pathologies of PD in the brain include intracellular misfolded protein aggregates of α-Synuclein oligomers (synucleinopathies) that form plaques called Lewy Body inclusions in the substantia nigra (Huang et al., 2015; Wang et al., 2016; Shahmoradian et al., 2019). These intracellular inclusions cause aberrant neurotransmission because, α-Synuclein is a SNAP-associated protein in neurons of the CNS, PNS and ENS that tethers and primes pre-synaptic vesicles for exocytosis (Killinger et al., 2019). Considering the similar effects of tau and β-amyloid to α-Synuclein proteins in neurotransmitter trafficking along the axon and release, it is not surprising that PD and AD are comorbid. Especially, since unresolved misfolded proteins with prion-like effects are characteristic of both diseases (Xie et al., 2014).

Evidence of the seeding of parkinson disease in the gut prior to the brain

Recent works demonstrated that, α-Synuclein can be detected in the ENS years before clinical onset of PD, similar to tau and β-amyloid (Hawkes et al., 2010; Shannon et al., 2012; Devos et al., 2013; Driver-Dunkley et al., 2014; Hilton et al., 2014; Iranzo et al., 2014; Stokholm et al., 2016). This α-Synuclein accumulation causes constipation and inflammation of the gut that often leads to Inflammatory Bowel Disease (IBD) (Barbut et al., 2019; Brudek, 2019; Chen et al., 2019). As mentioned in the previous section, studies in PD rodent models have shown that α-Synuclein seeded in the enteric neurons of the colon, duodenum, and stomach (Shannon et al., 2012; Sánchez-Ferro et al., 2015; Kim et al., 2019; Challis et al., 2020) migrate via the vagal nerve to the brain (Braak et al., 2003; Holmqvist et al., 2014; Uemura et al., 2018). This was demonstrated in experiments where the α-Synuclein-rich lysate, prepared from severely affected PD patient substantia nigra brain tissue, was injected into the intestines of wild type rats leading to the detectable accumulation of α-Synuclein over time in both the DMV and the brain (Holmqvist et al., 2014). This study also showed that α-Synuclein was selectively up-taken by the DMV compared to BSA. Notably, α-Synuclein accumulated at the Dorsal Motor nucleus of the vagus nerve (DMV), a collection of cholinergic neurons. Furthermore, DMV migration of α-Synuclein was prevented by a vagotomy of the base-afferent vagal nerve, as demonstrated by (Kim et al., 2019) (Figure 2). Therefore, cholinergic neurons must facilitate long-distance translocation of α-Synuclein (monomer, oligomer, and fibril) via a microtubule-associated transport mechanism (Holmqvist et al., 2014). By this notion, the question that surfaces is whether the α-Synuclein inclusions in the DMV are the reason behind the GI issues observed in PD patients, or if the symptoms are the reason for the aggregation of α-Synuclein, exacerbating symptoms and pathology in the DMV.

FIGURE 2

FIGURE 2. α-Synuclein progressively translocates from the gut into the brain: experimental diagram and result. (A) PFFs Pathologic α -Synuclein (pSer129- α -syn), as Pre-Formed Fibrils (PFFs), were injected into the duodenum and pylorus of a mouse. Translocation of Pre-Formed Fibrils (PFFs) of Pathologic α-Synuclein from the uppermost division of the small intestine was facilitated by the nodose ganglion (the vagal nerve afferents of the mouse). To confirm the credibility of this migratory route, the anterior trunk of the vagal afferents were severed (site of vagotomy). PFFs were not identified in the brains of the mice that received an anterior trunk vagotomy. (B) The graphs represent the progressive translocation of PFFs from the gut into the brain after 1–10 months from the injection. At month one post injection, the α-Synuclein PFFs translocates into the brain, first appearing at the Medulla Oblongata (MO). The trans-neuronal propagation and migration of the PFFs into the mouse brain proceeded from the posterior MO to the mouse brain’s anterior Olfactory Bulb (OB) (MO to OB). Within 1 month post injection, PFFs were detected in the Dorsal Motor Nucleus of the Vagus nerve (DMV) of the MO, and Locus Coeruleus (LC) of the Pons. At 3 months post injection, the abundance of PFFs in the Amygdala (AMG) spiked, while trace amounts of PFFs in the substantia nigra para compacta (SNc), Hippocampus (HIP), and Pre-Frontal Cortex (PFC) were detected. At 7 months post-injection, PFFs were detected in the Striatum (STR) and olfactory bulb (OB). Finally, at 10 months PFF has infiltrated and diffused through the entire brain. Data extracted and modified from (Kim et al., 2019). Figure constructed on BioRender.com.

Several studies have confirmed the migration of α-Synuclein from the ENS (Challis et al., 2020), by tracking fluorescently tagged-α-Synuclein, inoculated into the intestines of mice. The tagged-α-Synuclein translocated from the gut to the brain, and created human Parkinson-like symptoms, that affected sensorimotor behaviors including diminished ability of mice to climb down a pole or hang from a metal wire for an extended period of time. In addition, abnormalities in GI function as well as inflammation were reported in mice that received an intestinal injection of tagged-α-Synuclein. This recapitulated symptoms experienced by pre-clinical human PD patients (i.e. constipation and bowel inflammation) (Dinan and Cryan, 2017; Challis et al., 2020). Therefore, α-Synuclein pathogenesis can be seeded in the gut and ultimately, via the gut-brain axis, move to the brain. However, we still need to understand what triggers the accumulation of α-Synuclein in the intestine and leads to pathogenesis.

Implication of diet and microbes in the pathology of PD

Since IBD and therefore intestinal inflammation occurs in PD patients before the brain pathologies begin, diet and commensals are suspected to play a role in the formation of α-Synuclein Lewy bodies (Rinninella et al., 2019; Mertsalmi et al., 2020). Mitochondrial abnormalities are observed in the gut of IBD (Jackson and Theiss, 2020), and PD (Brudek, 2019) patients. Protein α-Synuclein aggregates have been found to cause mitochondrial damage by interacting with complex-I of the electron transport chain, and slowing down mitochondrial metabolism (Kamp et al., 2010; Faustini et al., 2017). This type of mitochondrial stress increases the redox state of intestinal epithelial cells and creates inflammation (Friedman and Nunnari, 2014; Console et al., 2020). Therefore, α-Synuclein in PD might act just like β-amyloids and tau in AD, as a facilitator and amplifier of PD by seeding pathology in the gut, ultimately affecting the brain (Braak et al., 2003; Kitani-Morii et al., 2021). As for AD, the pathology in the gut could be influenced by oxidative stress and tissue inflammation of the gut that enhance protein aggregate formation and/or gut permeability that is translated to the brain, causing neuronal death and impairment of memory and locomotion. Thus, protein α-Synuclein aggregates in the gut can transfer to the brain or can generate local inflammation that distally impacts the BBB and neuronal activity as reported of Aβ amyloids.

Additionally, several genome-wide association studies revealed that mutations in leucine-rich repeat kinase 2 (LRRK2) that are one of the greatest genetic contributors to PD are also linked to increased incidence of Crohn’s Disease (CD), a form of IBD (Hui et al., 2018). Although to date, the pathology of CD does not include neuropathology, CD is characterized by an increase in leakage of the epithelium, inflammation, and dysbiosis in the GI, all features that seem to contribute to neuroinflammation and neuropathology in PD. Therefore, further studies looking at the role of LRKK2 in CD could help to define the mechanisms of the disease of PD and the role of gut-brain communication in the PD pathogenesis.

Overall, NDs such as AD and PD do not arise exclusively from defects in the brain, but signals coming from peripheral organ environments and inter-organ interaction can wire messages to the brain and effect the brain. Therefore, more studies are required to dissect the mechanisms of action of the DMGB in health and NDs. Fortunately, the use of multidisciplinary approaches and more amenable model organisms will fast-track our knowledge in this field.

Model systems to study the DMGB axis in neurodegenerative diseases

Recent efforts to unravel the diet-microbiota-gut-brain networks have relied on genome-wide association studies and metagenomic data in small cohorts of human samples to identify disease-associated factors. It is now clear that to dissect the mechanism underlying such multifactorial diseases, the use of multidisciplinary approaches with heavily controlled, reductive model systems is an enormous asset. Various model systems have been developed to study NDs primarily in the brain (see table 1), and currently being developed for the gut to study the gut-brain axis (discussed below).

TABLE 1

TABLE 1. Models of Mus musculus (Mouse) and Drosophila melanogaster (Fruit fly) for studying the human neurodegenerative disease. The reported models represent Tauopathies, β-amyloidopathies, and Synucleinopathies in the brain. Models include Knock-out (KO), Knock-in (KI), Knock-Down (KD), and Over-Expression (OE) of hallmark genes for each of the three categories of neurodegenerative disease listed above. There is a column describing similarities in pathology between species and another column for differences. With each example made, there are references to the literature for more information about the model organism’s pathologies and similar or contrasting human pathology for comparison.

The murine model system to study NDs

The mouse mammalian model system in particular presents 90% synteny to the human genome (Monaco et al., 2015) and has been used in over 95% of studies of human disease (Vandamme, 2014). Mouse models of NDs have facilitated the study of neurodevelopmental and neurological diseases, and advanced our understanding of the molecular pathogenesis of NDs in humans (Dawson et al., 2018; Zhao and Bhattacharyya, 2018). In particular, the models that produce similar ND pathologies within the most conserved region of the mouse brain, the neocortex, have been extensively used (table 1). For example, transgenic or knockout (KO) mouse models for tau, β-amyloid, and α-Synuclein (table 1) have been used to investigate the physiological roles of the familiar forms of PD genes and to model dopaminergic degeneration caused by the dysfunction of these genes. Although these models exhibit various pathological and behavioral phenotypes, some aspects of PD pathogenesis such as the degeneration of distinct dopaminergic neurons or NFTs have not been reproduced (Harada et al., 1994; Cabin et al., 2002; Hasegawa et al., 2009; Chen et al., 2022).

In context of the intestinal epithelium, mice have also been extensively used in biomedical disease studies of intestinal dysplasia and inflammation such as IBD, or infection models to better understand the pathogenesis of gut-borne pathogens (Gkouskou et al., 2014; Vandamme, 2014; Stanford, et al., 2020). The fundamental gross/cellular anatomy of the mouse gut is also very similar and has been considered one of the best comparable animal models to the human gut (Figure 3) (Trinder et al., 2017; Stanford et al., 2020).

FIGURE 3

FIGURE 3. A cross-comparison of the gastrointestinal tract gross anatomy, gut microbiota composition, and general intestinal epithelial architecture between Drosophila melanogaster (Fruit fly), Mus musculus (Mouse), and Homo sapiens (Humans). In the small intestine, for mouse and human, and midgut, for the fruit fly, all three species share Firmicutes and Bacteroidetes microbial population as the dominant resident phyla. Figure constructed on BioRender.com, pie charts of common phyla that compose the gut-microbiota are referenced from (Trinder, et al., 2017).

With regards to studies defining the effect of microbiota on animal physiology, the mouse has one of the most similar gut-commensal populations to the human when comparing the presence and abundance of major phylogenetic groups, such as Firmicutes, and Bacteroidetes (Figure 3) (Xiao et al., 2015; Trinder et al., 2017). However, studying the highly-intertwined DMGB axis is more challenging in a complex mammalian system where the cost and infrastructural hurdles of constructing germ-free mouse models is high. Moreover, it is very difficult to control multiple factors while performing experiments where environmental changes may greatly influence the results (Trinder et al., 2017). These challenges together with the high cost and time required to generate these models add further risk to the use of such models given the overarching difficulty in knowing if the phenotypes observed accurately recapitulate disease states in humans (Vandamme, 2014). These issues have prompted researchers to incorporate alternative model organisms for these studies.

An emerging model system to study DMGB axis: D. melanogaster

In the last 10 years, the Drosophila model system has been affirmed as a valid model organism to unravel the mechanisms underlying NDs. Drosophila share similar gross organ function and inter-organ communication networks with mammalian systems (Figure 3; Figure 4) (Prüßing et al., 2013; Cassim et al., 2018; Jahromi et al., 2020), and carry many conserved genetic, cellular, and metabolic factors with mammals (Figure 4) (Cassim et al., 2018). For example, the nervous system of the fly has functionally analogous brain regions to the mammalian brain, such as the mushroom body for learning and memory, analogous to the mammalian hippocampus, the blood-brain barrier and the central complex for movement; comparable to the basal-ganglia and precentral gyrus in humans (Barnstedt et al., 2016; Gomez-Marin et al., 2016). Moreover, the nervous system of both flies and mammals shares similar mechanisms of neurotransmission, i.e. dopamine in dopaminergic neurons of the central complex in Drosophila facilitate locomotion, as the basal ganglia does in mammals (Martin and Krantz, 2014). Moreover, studying NDs in Drosophila allows studies where the environment can be easily controlled, large populations can be easily obtained and analyzed at lower costs, and where complex networks can be quickly dissected due to the availability of elegant genetic tools (Figure 4). Transgenic AD and PD models, that present similar behavioral/cellular pathologies to human NDs, have been successfully constructed expressing canonical human-linked alleles of NDs such as α-Synuclein and β-secretase. Furthermore, the characterization of these models has yielded great advances into the basis of neurodegenerative disease etiologies (Jeibmann and Paulus, 2009; Lu and Vogel, 2009; Perrimon et al., 2016; Tan and Azzam, 2017; Cassim et al., 2018; Xiong and Yu, 2018), therefore, making the human disease easier to study in less complex, but analogous, organism.

FIGURE 4

FIGURE 4. The diagram summarizes the main features that make Drosophila melanogaster a suitable model organism to study DMGB axis.

Core immuno-inflammatory pathways such as Toll, JAK/STAT, and immunodeficiency (Imd) equivalent to TLR-4, JAK/STAT and TNF pathways in mammals (Hoffmann and Reichhart, 2002; Hoffman, 2003; Myllymäki et al., 2014) are also present in Drosophila. These innate immune-inflammatory pathways, whether in humans or Drosophila, respond to infection and aging/injury by promoting the expression of inflammatory mediators such as cytokines and antimicrobial peptides (AMPs in fly and humans) (Myllymäki et al., 2014). During the progression of NDs in humans, the release of inflammatory mediators by the innate immune cells (e.g. microglia) leads to systemic inflammation that ultimately can contribute to inflammation of the brain and neuronal damage (Lye and Chtarbanova, 2018; Arora and Ligoxygakis, 2020). Typically, AMPs during infection are neuroprotective, but during aging their constitutive expression in the brain elicit neurotoxic effects that might trigger/exacerbate neurodegeneration (Cao et al., 2013; Kounatidis et al., 2017; Lye and Chtarbanova, 2018). Accumulation of these inflammatory molecules during aging is not necessarily caused by local secretion of AMPs in the brain but can come from peripheral organs. For example, a study carried out in the intestinal epithelium of Drosophila showed that over-aging PINK1-mutant flies (PD model), exhibit accumulation of damaged mitochondria in intestinal epithelial cells that activate NF-kB and expression of AMPs that lead to gut dysfunction (Fedele et al., 2020). The high AMP expression leads to age-dependent neurodegeneration. Genetic suppression of NF-kB activity in aging Drosophila intestines improved the neurodegeneration phenotype.

In another recent study, the authors examined the role of AMPs on fly’s lifespan over aging. They found that while ablation of individual AMP genes does not impact the animal lifespan during aging, on the other hand, the lack of 14 AMP genes impacts lifespan over aging. Hanson and Lemaitre demonstrate that AMPs control the gut microbiota over aging and protect animal survival, thus demonstrating the importance of gut-microbiota interaction during animal aging (Hanson and Lemaitre, 2022).

These studies strengthened the validity of Drosophila as a model system to dissect the mechanism of the microbiota-gut-brain axis in NDs. Moreover, the Drosophila GI tract has been researched over decades in regard to interorgan communication and inflammation (Capo et al., 2019; Hung et al., 2020; Okamoto and Watanabe, 2022). The blueprint of the intestine is functional and structurally analogous to humans (Figure 3). For a complete review of Drosophila’s intestine we refer the reader to (Capo et al., 2019). The Drosophila midgut epithelium, functionally analogous to the mammalian small intestine, is composed of four different cell types. Progenitor cells are intestinal stem cells, and undifferentiated intestinal stem cell daughters referred to as enteroblasts can differentiate into enterocytes, or into enteroendocrine cells in response to diverse and incompletely defined differentiation signals (Figure 3). Among these cells, the enteroendocrine cells function to integrate gut environmental signalling such as dietary nutrients and microbiota-derived metabolites, secrete peptides and cytokines and regulate various physiological processes. Several enteroendocrine cell-derived peptides act locally to regulate gut motility (Okamoto and Watanabe, 2022), proliferate intestinal stem cells (Amcheslavsky et al., 2014; Takeda et al., 2018), modulate lipid metabolism in enterocytes (Song et al., 2014; Kamareddine et al., 2018), and release endocrine factors for interorgan communication. Genetic experiments strongly suggest effects of several enteroendocrine-derived peptides on remote target organs or tissues such as the CNS (Kubrak et al., 2022).

Research with Drosophila has also contributed to our understanding of the importance of the microbiota homeostasis for an organism’s health (Douglas, 2018). In both Drosophila and humans, gut microbiota abundance and diversity are dependent on the host’s diet (Chaston et al., 2014), host’s immune system (Marra et al., 2021), gut morphology (Broderick et al., 2014), health status and hosts genotype (Clark et al., 2015; Fischer et al., 2017; Téfit and Leulier, 2017). Although the gut-commensal profile of Drosophila harbors a lower microbial diversity compared to that found in the mammalian gut (Bakula 1969; Chandler et al., 2011; Corby-Harris et al., 2007, with <30 taxa in the fly (Newell and Douglas, 2014), there are still many phylogenetically common species shared with humans (i.e. Firmicutes, the most abundant phyla in both species) (Figure 3), which makes this animal an amenable model to study fundamental gut-commensal interactions (Newell and Douglas, 2014; Trinder et al., 2017; Douglas, 2018). Interestingly, these bacterial species display similar health-promoting proprieties in Drosophila and mammals (Erkosar et al., 2013). For instance study of microbiota in transgenic fly models for NDs have revealed correlation between shift in microbial population and aging (Kitani-Morii et al., 2021; Neophytou and Pitsouli, 2022; Schretter, 2020; von Frieling et al., 2020) or the onset of NDs similar to that observed in humans (Mertsalmi et al., 2020; Rydbom et al., 2021).

Considering these benefits, Drosophila could complement the information gathered from the murine models of NDs and can be considered one of the most versatile model organisms to study the DMGB axis in the context of diseases such as NDs and interorgan communication.

The diet-microbiota-gut-brain axis drives neurodegeneration in mice and the flies

The diet-microbiota-gut-brain axis is a rapidly expanding area of research suggesting that the interaction between the intestine, gut-commensals, and diets define the gut-brain signaling by means of neuronal, endocrine, immune, and humoral links that overall impact the brain (Carabotti et al., 2015; de Wouters d’Oplinter et al., 2021; Kitani-Morii et al., 2021). In the following section, we will summarize each component of the DMGB axis and will report results from studies that have established how dysfunction of this axis might be an early sign for the onset of NDs.

The diet-microbiota-gut-brain axis: The diet

Nutritional replenishing of our energy expenditure impacts numerous aspects of our physiology and dictates the level of individual protection or risk factors for developing diseases such as NDs (Cena and Calder, 2020). Clinical and animal studies highlight the importance of dietary lipids throughout life from neural development to aging and neurodegeneration (Calon and Cole, 2007; Belkind-Gerson et al., 2008; Innis, 2008; Bousquet et al., 2009; Barrett et al., 2014; Chianese et al., 2018; Stavrinou et al., 2020).

Dietary fatty acids can directly affect the brain by crossing the BBB and subsequently changing the neural membrane composition (Chianese et al., 2018). A diet rich in mono and polyunsaturated fatty acids (monounsaturated fatty acids and PUFAs), is associated with anti-inflammatory properties (Tosti et al., 2018). Long-chain dietary n-3 PUFAs, eicosapentaenoic acid, and docosahexaenoic acid, play a regulatory role in immunological responses. They suppress genes involved in inflammation and change the cell membrane composition by displacing n-6 PUFA and cholesterol (Scaioli et al., 2017). Consequently, they alter lipid raft aggregation and affect cell signaling (Scaioli et al., 2017). Eicosapentaenoic acid, docosahexaenoic acid, cholesterol and sphingolipids are also of great importance for brain function influencing cell trafficking and acting as second messenger molecules in signal transduction. On the other hand, western diets that are rich in saturated fats, have pro-inflammatory properties (Christ et al., 2019). Saturated and trans-fatty acids, and n-6 PUFAs mimic the actions of LPS-inducing pro-inflammatory processes which compromise intestinal barrier integrity as demonstrated in studies in mice (Guo et al., 2013; Williams et al., 2013).

These pro- and anti-inflammatory diets might indirectly influence neuroinflammation via the intestine, microbiome, and vasculature.

The host metabolism and dietary lipids in inflammation

The effects of dietary lipids on animal physiology are heavily regulated at the cellular level by individual metabolism. Cellular organelles, such as mitochondria and peroxisomes, play central roles in dietary lipid catabolism/anabolism and productions of lipid mediators vital for signaling and metabolism. These organelles influence the impact that dietary lipids have on animal physiology. Very long-chain fatty acids (VLCFAs) derived from vegetable oils, nuts, and seeds (Tenreiro et al., 2013) are normally catabolized by peroxisomes and can be lipotoxic to any tissue if not metabolized. Accumulation of VLCFAs is linked to neurodegeneration and has been found in AD brains along with reduced peroxisome activity (Kou et al., 2011). A study carried out in D. melanogaster (Di Cara et al., 2018), found that peroxisomal dysfunction specifically in the intestinal epithelial cells damages intestinal epithelial integrity resulting in dysplasia, and promotes the systemic accumulation of non-esterified fatty acids. These fatty acids trigger intestinal inflammation and decrease animal survival, confirming that abnormal lipid metabolism affects inflammation. Likewise, the oxidation of long-chain fatty acids by mitochondria is protective, as mitochondria defects lead to an accumulation of long chain fatty acids in the gut epithelium which induces high levels of oxidative stress (Swanson et al., 2012; Custers et al., 2022) and inflammation that affects ENS neurotransmission (Chen et al., 2019).

The brain has the highest cholesterol content in the body as the main component of axonal myelin sheets, essential to maintain the physiological functions of the brain such as cognition and movement (Rhea and Banks, 2021). An excess of cholesterol can be damaging and therefore needs to be oxidated into the oxysterol 24S-OH-Chol by the neuronal enzyme CYP46A1. 24S-OH-Chol is then released into the circulation by neurons and eliminated. As oxysterols can diffuse through plasma membranes, they can then cross the BBB. AD patients show a reduction in circulating levels of 24S-OH-Chol, because of decreased expression of the CYP46 enzyme in neuronal cells. Oxysterols are also present in plasma mainly in the form of 27-OH-Chol as a product of the mitochondrial CYP27A1 enzyme activity in the liver. Recent works suggested that 27-OH-Chol accumulation triggers AD-related pathological changes. Rabbits fed a cholesterol-rich diet showed increased serum cholesterol, increased 27-OH-Chol in the hippocampus, and pathological hallmarks similar to those found in AD, such as microglia activation, brain atrophy, and cognitive deficits (Brooks et al., 2017). Therefore, it is suggested that dietary cholesterol could induce neurodegeneration if there is excessive production of 27-OH-Chol by the mitochondria in the liver.

Diet and microbiota-derived metabolites in NDs

Important lipids for most physiological functions are not just dietary derived but are also products of gut microbiota metabolism. In mice and humans, it has been shown that the gut microbiota can affect lipid metabolism and lipid levels in the blood and different tissues (Chatelier et al., 2013; Cotillard et al., 2013; Lam et al., 2015; Just et al., 2018). However, dietary lipids can also alter the gut microbiota composition either by acting as substrates for bacterial metabolic processes or by diminishing bacterial growth due to their toxicity towards certain bacterial species (e.g. Bacteroides, Clostridium, and Roseburia) (Agans et al., 2018; Schoeler and Caesar, 2019). As a result, dietary lipids can shape their own metabolism by altering the balance of enteric bacteria that are able to metabolize them. SCFAs in particular are the metabolic end-products of gut-commensal fermentation of fibrous food, that have neuroprotective roles (Onyango et al., 2015; Dinan and Cryan, 2017; Baxter et al., 2019; Custers et al., 2022). For example, in a study conducted by (Kong et al., 2018), 16S rRNA gene sequencing and gas chromatography-mass spectrometry analyses in a Drosophila model of AD, showed decrease of Lactobacillus and Acetobacter species that correlate to a dramatic decrease of SCFA acetate, which is the most abundant SCFA. Concurrently, in Drosophila models of PD, the administration of sodium-butyrate reduces degeneration of dopaminergic neurons and improves the locomotor defects in a pan-neuronal transgenic fly model expressing mutant-human-α-Synuclein (St Laurent et al., 2013). SCFAs have also been linked to the maintenance of gut and immune homeostasis in mammalian systems, demonstrating a neuro-immunoendocrine regulatory role in the brain (Silva et al., 2020; Chen et al., 2022). For example, dietary butyrate has an anti-inflammatory effect in the gut (Baxter et al., 2019) and in the brain by influencing BBB permeability (Chen et al., 2022).

Vitamins and NDs

Other nutrients such as vitamins also influence gut and brain health through their antioxidant activities (Qi et al., 2019; Hung et al., 2020; Komleva et al., 2021). Dietary vitamin group B, such as B3 (niacin), B9 (folic acid), and vitamin B12 (cobalamin) effect learning, memory, and overall cognition (Virmani et al., 2013; Staff and Windebank, 2014). Vitamin B3 (niacin) improves locomotor deficits of PD patients and PD Drosophila models (Jia et al., 2008; Wakade et al., 2021). In a double blind-study conducted by (Wakade et al., 2021), 47 patients were given either a placebo or niacin supplements. After 12 months of daily supplementation and clinical tests assessing motor and non-motor quality of life symptoms and biochemical tests assessing inflammatory cytokine profiles, 42 patients exhibited an improvement in motor, and cognitive symptoms. Additionally, while the levels of many inflammatory cytokines did not change, anti-inflammatory cytokine IL10 was upregulated. Other essential vitamins of group of B do not derive from the diet but are supplied by the microbiota (Morowitz et al., 2011; Virmani et al., 2013). Therefore, dietary metabolites, not just lipids, may have neuroprotective activities within the DMGB axis to prevent the onset of NDs.

The diet-microbiota-gut-brain axis: The gut microbiota

Over 100 years ago Elie Metchnikoff, Nobel Prize laureate for his discovery of the macrophage and phagocytosis (Dinan and Cryan, 2015), dedicated the last years of his career to the study of longevity. He proposed that people in Eastern Europe lived longer due to the high amounts of fermented foods they ate, which contained lactic acid bacteria. Later studies in germ-free mice demonstrated that germ-free animals lived longer than controls (Gustafsson 1946), suggesting that a direct link exists between microbiota, microbiota-derived metabolites, and aging. It is now well established that the microbiota and brain can communicate through different routes.

Microbiota-brain communication via DMV

One line of communication between the gut microbiota and the central brain occurs via the DMV as shown by studies in mice demonstrating the anxiolytic effect of intestinal Bifidobacterium longum on animals that were subject to vagotomy (Bercik et al., 2011). As discussed above, it has also been proposed that commensal bacteria can secrete prion-like peptides that could trigger other proteins in the gut to aggregate (Chen et al., 2016; Chen et al., 2019). These misfolded aggregated proteins then spread through the intestine and the ENS to the brain. Protein aggregation of NDs peptides reach the brain via the DMV and a prion-like mechanism (Braak et al., 2003). This hypothesis was confirmed from preliminary data in Rattus norvegicus fed with bacteria that produce the prion-like protein, curli, which resulted in α-Synuclein deposition accumulation in the gut and brain (Chen et al., 2016).

Microbiota as a source of neurotransmitters

The gut microbiota also communicates with the brain by altering the level of neurotransmitter precursors. For example, high concentrations of Bifidobacterium infantis have been shown to increase plasma tryptophan levels and thus influence central 5-hydroxytryptamine transmission (Desbonnet et al., 2008; O’Mahony et al., 2015). Furthermore, commensal bacteria can synthesize and release neurotransmitters, such as the inhibitory neurotransmitter γ-aminobutyric acid (GABA), which can be produced by Lactobacillus and Bifidobacterium species. Likewise, Candida, Streptococcus, Escherichia, and Enterococcus species have been reported to produce serotonin, Bacillus can produce dopamine, and certain Lactobacillus species can produce acetylcholine (Lyte, 2013; 2014). These microbially synthesized neurotransmitters cross the mucosal layer of the intestines and mediate physiological events in the brain. Likewise, SCFAs such as propionate, butyrate, and acetate, are also important metabolic products of gut microbial activity. These SCFAs can affect the brain indirectly or directly either by acting as ligands for G-protein coupled receptors or in the case of butyrate as epigenetic modulators of histone deacetylases to control transcriptional changes that affect neuronal functions (Galland, 2014; Stilling et al., 2014; Canfora et al., 2015; Paul et al., 2015; Stilling et al., 2016).

Microbiota composition and NDs

In its abundance, the human microbiome is composed of around 1.3 more cells than cells of the human body (>200 taxa) (Sender et al., 2016; Yang et al., 2020), acting like a major organ system that contributes to physiological health. In fact, dysbiosis of gut commensal populations leads to metabolic and inflammatory diseases (Dinan and Cryan, 2017). Neurological diseases, such as NDs are co-morbid with gastrointestinal alterations (Vandvik et al., 2004; Sampson and Sarkis, 2015). It has indeed been reported that in both mouse and Drosophila models of human PD, the neurodegenerative pathologies in the brain have been observed in concurrence with commensal dysbiosis in the gut (Erny et al., 2015; Challis et al., 2020; Peterson, 2020; Kitani-Morii et al., 2021; Rydbom et al., 2021).

At a phylum level, the microbiome is primarily defined by two dominant bacterial phylotypes, Bacteroidetes and Firmicutes with Proteobacteria, Actinobacteria, Fusobacteria and Verrucomicrobia present in relatively low abundance (Qin et al., 2010; Lankelma et al., 2015). In humans, mice, and Drosophila, the phyla Firmicutes dominate the gut, where the Firmicutes is composed of many Lactobacillus species (Newell and Douglas, 2014; Trinder et al., 2017; Douglas, 2018). These Lactobacillus species have been found to influence host metabolism and behavioral pathologies of NDs in various gut-commensal studies in mammals and Drosophila (Newell and Douglas, 2014). For example, L. plantarum in mammals influences gut-lipid metabolism, increasing butyrate which has anti-inflammatory effects (Storelli et al., 2011). In Drosophila, Lactobacillus plantarum also alters gut metabolism such as the insulin signaling pathway implicated in the pathogenesis of NDs (Storelli et al., 2011; Newell and Douglas, 2014; Spinelli et al., 2019; Komleva et al., 2021). Moreover, L. plantarum also ameliorates age-dependent memory impairment in the mouse (Castelli et al., 2021) and Drosophila models of NDs (Schretter et al., 2018; Schretter, 2020). Studies in Drosophila have identified Lactobacillus brevis as the culprit behind the locomotion deficit of PD pathogenesis in a Drosophila PD model (Schretter et al., 2018). Therefore, in humans, interaction of Lactobacillus, or other undiscovered or unrecognized species that influence the gut-brain axis may hold the key to unlocking the aetiologies of NDs. However, sequencing and understanding the human microbiome is much more complex than a mouse or a fly.

In humans, the gut microbiota has recently been sequenced in patients with PD in a study carried out by (Scheperjans et al., 2015). They performed metagenomic analyses of 72 PD patients and 72 matched controls. The results indicated a major reduction in the levels of Prevotellaceae in the patients and a positive association between the levels of Enterobacteriaceae and the severity of postural instability and gait difficulty. However, the authors did not claim either the temporal or causal relationship between the gut microbiota and the features of the disease. Another analysis of microbiota composition in PD pointed to a reduction in butyrate-producing bacteria in feces and Faecalibacterium in the mucosa of PD (Keshavarzian et al., 2015).

Despite all the encouraging studies pointing to the microbiota as a potential therapeutic target for PD, to date, there is no conclusive evidence as of yet showing that microbiota transplants can ameliorate PD pathology. More research is needed to determine the relative role of the microbiome in PD.

A detailed analysis of the microbiota in AD patients is lacking, preliminary data published in preprint format has implicated the microbiota in the accumulation of amyloid plaques in a mouse model of AD (Harach et al., 2015). In this study, the authors generated a transgenic AD mouse model under germ-free conditions and found a dramatic reduction of cerebral Aβ amyloid pathology when compared to AD animals, which had normal intestinal microbiota. Colonization of germ-free AD mice with microbiota harvested from conventionally raised AD mice dramatically increased cerebral Aβ pathology. This was similarly observed in another study showing that antibiotic treatment could limit Aβ pathology and neuroinflammation (Minter et al., 2016). These data offer hope for the future generation of a novel microbiota-based approach to ameliorate symptoms of AD.

Gut-brain communication also occurs via the immune system. Signaling from gut epithelial cell-secreted peptides, bacterial-derived molecules, and cytokines can activate gut resident immune cells to secrete gradients of cytokines that pass the BBB and communicate with cells in the brain. The activation of microglia, the brain’s resident immune cells, plays a central role in neuroinflammatory processes in aging and NDs (Jyothi et al., 2015). The activation of microglia appears to be influenced by the gut microbiome (Erny et al., 2015). This data suggested that neuroinflammation can be regulated by targeting the gut microbiome using probiotic approaches.

In conclusion, the microbiota-gut-brain axis is becoming increasingly recognized in the context of NDs. However, further research is needed to define how the microbes communicate with the host and to understand the interactions between the diet, the microbiota and the intestinal epithelium.

The diet-microbiota-gut-brain axis: The gut

The GI tract and ENS interactions

The GI tract is a very complex organ with essential functions such as absorbing and processing of ingested food to fulfill the energy demands of development, reproduction, and survival (Woods et al., 1998). The GI tract is also a major source of neuronal and endocrine signals, which modulate food intake and the activity of other organs, such as the pancreas and the brain (Kabouridis and Pachnis, 2015; Abot et al., 2018). Additionally, the GI tract forms the largest and most important immune epithelial barrier against external dangers posed by ingested pathogens. Under ideal circumstances, the GI tract maintains a mutualistic and symbiotic relationship between a diverse and dynamic community of microorganisms and the host (Peterson and Artis, 2014; Abot et al., 2018). Here we will review the mechanisms by which the gut and gut-microbiota interactions might influence the brain activities in health and in the context of NDs while we refer the readers to a review by (Richards et al., 2021) for a detailed description of the mechanisms of gut-brain communications. The GI tract is also host to the ENS, a highly dense neuronal network that acts independently of the CNS (Fleming et al., 2020). The ENS presents a similar organization to the CNS brain regarding structure, function and pluri-chemical transmission. ENS neurons modulate a range of physiological activity, such as gut motility, intestinal permeability, intestinal immunity, enteric reflex, and enteroendocrine signaling (Carabotti et al., 2015), therefore playing a role in local inflammation (Fleming et al., 2020). The ENS communicates with the CNS via three primary neuronal types, intrinsic primary afferent neurons, motor neurons, and interneurons (Fleming et al., 2020). Communication between the neurons of the ENS and the PNS/CNS are carried out by compounds like acetylcholine, and reactive nitrogen species like Nitric oxide (Fleming et al., 2020). The primary method of communication between the ENS and CNS is facilitated by the bidirectional, 10th cranial nerve, the DMV in mammals and Drosophila (Breit et al., 2018).

The DMV is the main contributor of the parasympathetic nervous system. Exiting the medulla oblongata, the DMV delivers impulses from the brain to innervate peristalsis/digestion during a parasympathetic relaxed state. In return, the intestinal epithelium delivers signals to the brain communicating the state of the gut through the ENS via the DMV. The efferent vagal nerves regulate gastrointestinal secretory and motor function, and also the activity in the endocrine system of the gut, while the vagal afferents allow gut-brain information flow from the gut to the CNS. Vagal afferent signaling has been implicated modulating mood and affect, including distinct forms of anxiety and fear and are involved in the activation/regulation of the Hypothalamic Pituitary Adreno axis, which coordinates the adaptive responses to stressors of any kind (Tsigos and Chrousos, 2002; Howland, 2014). The DMV also has an immunomodulatory role as the cholinergic anti-inflammatory pathway (Goverse et al., 2016; Breit et al., 2018), making the DMV a major component of the neuroendocrine-immune axis. The appearance of pathogens in the gut activates resident innate immune cells to release cytokines. These in turn activate sensory fibers that ascend the DMV. Increasing efferent signals in the DMV suppresses peripheral cytokine release through macrophage nicotinic receptors and the cholinergic anti-inflammatory pathway. Thus, experimental activation of the cholinergic anti-inflammatory pathway by direct electrical stimulation of the efferent DMV was found to inhibit the synthesis of TNF-α in the liver, spleen, and heart, and lowers serum concentrations of TNF-α (Borovikova et al., 2000; Bernik et al., 2002). This regulation of the local and systemic inflammatory signals is essential to reduce metaflammation linked to neuroinflammation.

Humoral factors of the gut-brain communication

Gut communication to the brain does not solely rely on neurotransmission through the DMV but it can also be humoral through the secretion of metabolites processed from the diet by the microbiota or the gut epithelium. Metabolites can have neuroprotective trophic action (Liu, 2018) promoting neuron survival and plasticity in both the ENS and the CNS (Figure 1) (Liu et al., 2019). In a study conducted by (Vidal-Martínez et al., 2016) and colleagues, transgenic mice overexpressing mutant human α-synuclein developed PD-like enteric neuropathology. The animals accumulated α-synuclein aggregates in the intestinal epithelium and ENS nerves and exhibited gut motility problems that result in constipation. Treatments with FTY720, a sphingosine analog rescued the defects in the α-synuclein transgenic mice. FTY720 mediated the accumulation of the brain-derived neurotrophic factor that activates TrkB receptors in the gut reducing ENS synucleinopathy and improving gut motility (Vidal-Martinez et al., 2016).

The ENS and the intestinal epithelial cells also release peptides that can have local or distal effects. The battery of neuropeptides released in the intestines can affect the immune system or the CNS to control inflammatory responses, hormonal secretion, and metabolic activities. Gut peptides are mainly secreted from enteroendocrine cells in the GI tract. Neuropeptides and peptide hormones are released mainly by cell of the CNS and ENS executing in response to stress, metabolic, and commensals signaling. The Neuropeptide Y (NPY) is involved in controlling inflammation, pain, emotion, mood, cognition, stress responses, and metabolism. In the gut, NPY is expressed mainly by the ENS, where it regulates enteric inflammation. This is demonstrated by the observation that NPY-containing nerve fibers of the ENS are in close contact with immune cells in the mouse ileum lamina propria (Shibata et al., 2008). Specifically, NPY promotes colonic inflammation. A growing body of literature, both in humans and rodent models, suggests that brain NPY levels are altered in some neurodegenerative and neuroimmune diseases. NPY stimulates neuronal survival and neuroproliferation, attenuates neuroinflammation, and counteracts depressive symptoms and weight loss present in NDs. Ultimately, the extent to which these enteric peptides expression/repression in the gut is linked to NDs pathogenesis has not been established yet and the topic requires further investigation.

The immune system in the GI tract heavily influences gut-brain communication

The intestinal immune cells constantly face a large number of antigens that are obtained from either food or the intestinal microbiota. Intestinal CD4⁺ T helper cells are highly involved in mucosal immunity. Enteric glial cells are essential for the integrity of the bowel. The presence of different bacterial species determines the pro- or anti-inflammatory state of CD4⁺ T-cells (Ivanov et al., 2009), which highlights the importance of the intestinal microbiota in the preservation of mucosal homeostasis. Failure to inhibit pro-inflammatory immune responses increases intestinal inflammation and may contribute to the development of immune-mediated inflammatory diseases. A loss of enteric glial cells also leads to severe inflammation of the intestines. The increased inflammation of the gut affects the permeability of the intestinal barrier activating resident immune cells and leading to the accumulation of inflammatory mediators and microbial-derived metabolites such as LPS in the circulatory system triggering systemic inflammation and metabolic dysfunction (Lancaster et al., 2018). Humoral pathways of gut inflammation spreading to the brain can damage the BBB. Multiple reports have shown that the BBB is damaged in PD patients (Pisani et al., 2012) and LPS (Gray and Woulfe, 2015) induced PD animal models exhibited disrupted BBB (Varatharaj and Galea, 2017). If the BBB is damaged, proinflammatory cytokines and immune cells such as T-cells (Engelhardt, 2017) and mast cells (Jones et al., 2019) from peripheral inflammation are able to enter the brain. These series of events are now considered the current model mechanism of disease of NDs that could be applied to familiar and sporadic forms of NDs and support a scenario that points at peripheral inflammation and alteration of the DMGB as main triggers of pathogenesis.

Metabolic alteration in the GI as markers of NDs

Metabolic alteration and inflammation of the intestine are two features observed in the most common NDs. How metabolic alteration occurs and what pathway is principally involved in the intestinal epithelium when the diseases seed, is not understood. Damage or functional alteration of essential organelles such as mitochondria and peroxisomes, have been found to accompany different pathologies of disease. Mitochondria and peroxisomes are highly metabolic cellular organelles, ubiquitously conserved across eukaryotes, from yeast to humans (Osellame et al., 2012; Smith and Aitchison, 2013; Baron et al., 2016). Both organelles participate in a broad range of conserved cellular-metabolic processes, most notably β-oxidation of medium-chain, long chain and very long-chain fatty acids, the anabolism and catabolism of complex signaling lipids such as phospholipids, and synthesis and turnover of reactive oxygen and reactive nitrogen species. These metabolites are essential for supporting cellular energetic processes, limiting redox stress, mitigating inflammation, and maintaining cell structure and signaling (Osellame et al., 2012; López-Armada et al., 2013; Smith and Aitchison, 2013; Di Cara, 2020). As mentioned previously, α-Synuclein inclusion bodies have been identified in the gut and enteric neurons of PD patients prior to the onset of disease, as well as in cases of inflammatory diseases that compromise the gut epithelial barrier (Hawkes et al., 2010; Challis et al., 2020; Derkinderen et al., 2021). α-Synuclein inclusions damage cellular mitochondrial functions, therefore, linking the diseases to metabolic and signaling dysfunction of mitochondria. However other studies reported that mitochondrial damage occurs before α-Synuclein inclusions appear.

Peroxisome dysfunction has not been directly linked to the onset of NDs. Cumulative evidence has reported that peroxisome dysfunction in the intestinal epithelium causes intestinal inflammation and dysplasia as reported in Drosophila gut-specific peroxisomal knock-down models by (Di Cara et al., 2018). In the same study, peroxisomes were also found to modulate the gut microbiota which, as discussed herein, changes in gut microbiota are tightly connected to inflammatory diseases including NDs. Clinical reports described that peroxisome numbers and metabolic activities are lower within neurons of the post-mortem brains of patients affected by NDs such as AD (Kou et al., 2011; Cipolla and Lodhi, 2017). In particular, post-mortem brains of AD patients have high VLCFAs (substrates of peroxisome β-oxidation) and in a parallel a decrease in ether-phospholipids (products of peroxisomal metabolism) (Kou et al., 2011).

Despite these correlations, more studies are needed to establish whether alteration of mitochondria and peroxisomes in the intestinal cells could be the culprit of the metabolic dysfunction that triggers the cascade to NDs.

Discussion

For decades the study of genetic-NDs have generated several theories on sporadic disease pathogenesis (Garden and La Spada, 2012) based on how the disease pathologically presents in the brain showing mitochondrial dysfunction, oxidative stress, aberrant neurotransmission and neuronal death. However, emerging evidence has proven that the pathologies characterized in the CNS might be a consequence of metabolic and inflammatory dysfunctions occurring in distal organs such as the gastrointestinal tract. As discussed in this review, β-amyloid plaques and α-Synuclein Lewy body inclusions that represent signs of disease in the brain of AD and PD respectively, have also been identified in enteric neurons (Barbut et al., 2019; Challis et al., 2020). These findings highlight how NDs are not confined to the brain as previously believed, and might be a product of bidirectional communication of the body with the brain via inter-organ communication/coordination to maintain tissue homeostasis (Peters, 2006; McHugh and Gil, 2018). Nutritional, neuronal, and inflammatory signals have been linked to NDs, thus, NDs should be studied in a multi-factorial way, where commensal, and intestinal metabolic signals that shape physiological processes should also be considered. Additionally, alteration of cellular organelles such as mitochondria and peroxisomes in the intestinal epithelium could be the culprit of the metabolic dysfunction that triggers aberrant DMGB axis communication, and in turn NDs. Damage to these organelles and their metabolic processes could occur years before the disease appears in people that develop PD or AD. Therefore, organelle dysfunction could be used as an early marker to measure DMGB axis activity as a predictor of disease. It remains to be investigated whether alteration of organelle metabolism initiates the process of metaflammation and therefore drives the cascade that leads to neuronal death and the accumulation of Aβ aggregates or α-Synuclein Lewis inclusion bodies.

Another open question that remains about the mechanisms of diseases of NDs, is whether the early distal signaling that leads to ND seeding in the brain comes exclusively from the diet-gut-brain axis or if this axis integrates metabolic and inflammatory signaling from other organs as well. For instance, the immune system has an integral part in triggering the oxidative stress and inflammation that contributes to neuronal death. Moreover, recent work identified that the liver as another integral contributor to this axis. This was specifically demonstrated in mice in which the hepatocyte-restricted expression of the human mutant variant of APP displayed peripheral metabolism of Aβ peptides and associated neurovascular inflammation, CNS neurodegeneration, and memory impairment. These animals exhibited an accumulation of triglyceride rich lipoprotein-Aβ in the circulation that might increase the permeability of the BBB, as well as the accumulation of cerebral neutral lipids and widespread aggregates and neuronal loss. This work suggests that hepatic metabolism of Aβ can cause neuroinflammation and AD. Thus, the question stands as to whether metabolic disturbances in one or multiple peripheral organs might happen in a defined sequence that ultimately consist in a disease risk factor. Dissecting these networks is a complex task and requires that all or at least many of these potential contributing factors are individually controlled. The establishment of Drosophila model organisms to study NDs will help to dissect the complex network of the DMGB axis and to identify whether multiple organs influence this DMGB axis in the etiology of NDs.

These new approaches that will help us investigate the origin of NDs outside the brain have expansive promise to identify early markers of disease or develop treatments capable of targeting novel molecular networks for disease prevention.

Author contributions

SM wrote the first draft of the manuscripts and designed the figures. FDC wrote the final version of the manuscripts and edited the Figures. BP provided feedback on the topics covered and edits on the final version.

Funding

This work was supported by Discovery Grant RGPIN/04083–2019 from the Natural Sciences and Engineering Research Council of Canada (NSERC), Research Nova Scotia Establishment Grant MED-EST-2019–2144, and a New Frontiers Research Funds-Exploration grant NFRF-E 19–00007 to FD.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Abbreviations

APP: Amyloid Precursor Protein; BBB: Blood Brain Barrier; BDNF: Brain Derived Neurotropic Factor; DMGB axis: Diet-Microbiota-Gut-Brain axis; DMV: Motor nucleus of the Vagus nerve; ICR: Institute of Cancer Research; NFTs: Neurofibrillary Tangles; PFFs: Pre-Formed Fibrils; SCFAs: Short Chain Fatty Acids; VLCFAs: Very Long Chain Fatty acids.

References

Aarli, J. A., Dua, T., Janca, A., and Muscetta, A. (2006). Neurological Disorders, public health challenges. Arch. Neurol. 54 (7), 1–232. doi:10.1001/archneur.1997.00550190066016

CrossRef Full Text | Google Scholar

Abot, A., Cani, P. D., and Knauf, C. (2018). Impact of intestinal peptides on the enteric nervous system: Novel approaches to control glucose metabolism and food intake. Front. Endocrinol. 9 (328). doi:10.3389/fendo.2018.00328

PubMed Abstract | CrossRef Full Text | Google Scholar

Adams, S. J., Crook, R. J., Deture, M., Randle, S. J., Innes, A. E., Yu, X. Z., et al. (2009). Overexpression of wild-type murine tau results in progressive tauopathy and neurodegeneration. Amn J. Pathol. 175 (4), 1598–1609. doi:10.2353/ajpath.2009.090462

PubMed Abstract | CrossRef Full Text | Google Scholar

Agans, R., Gordon, A., Kramer, D. L., Perez-Burillo, S., Rufián-Henares, J. A., and Paliy, O. (2018). Dietary fatty acids sustain the growth of the human gut microbiota. Appl. Environ. Microbiol. 84 (21), 015255–e1618. doi:10.1128/AEM.01525-18

CrossRef Full Text | Google Scholar

Ali, S. A., Begum, T., and Reza, F. (2018). Hormonal influences on cognitive function. Malays J. Med. Sci. 25 (4), 31–41. doi:10.21315/mjms2018.25.4.3

PubMed Abstract | CrossRef Full Text | Google Scholar

Allison, S. L., Fagan, A. M., Morris, J. C., and Head, D. (2016). Spatial navigation in preclinical alzheimer's disease. J. Alzheimer's Dis. 52 (1), 77–90. doi:10.3233/JAD-150855

CrossRef Full Text | Google Scholar

Amcheslavsky, A., Song, W., Li, Q., Nie, Y., Bragatto, I., Ferrandon, D., et al. (2014). Enteroendocrine cells support intestinal stem-cell-mediated homeostasis in Drosophila. Cell Rep. 9 (1), 32–39. doi:10.1016/j.celrep.2014.08.052

PubMed Abstract | CrossRef Full Text | Google Scholar

Anwal, L. (2021). A comprehensive review on alzheimer’s disease. World J. Pharm. Pharm. Sci. 10 (7), 1170. doi:10.20959/wjpps20217-19427

CrossRef Full Text | Google Scholar

Aparicio, R., Schmid, E. T., and Walker, D. W. (2022). Gut mitochondrial defects drive neurodegeneration. Nat. Aging 2, 277–279. doi:10.1038/s43587-022-00206-y

CrossRef Full Text | Google Scholar

Armstrong, R. A. (2017). Laminar degeneration of frontal and temporal cortex in Parkinson disease dementia. Neurol. Sci. 38 (4), 667–671. doi:10.1007/s10072-017-2828-6

PubMed Abstract | CrossRef Full Text | Google Scholar

Arora, S., and Ligoxygakis, P. (2020). Beyond host defense: Deregulation of Drosophila immunity and age-dependent neurodegeneration. Front. Immunol. 1, 1574. –13. doi:10.3389/fimmu.2020.01574

PubMed Abstract | CrossRef Full Text | Google Scholar

Ashraf, G., Greig, N., Khan, T., Hassan, I., Tabrez, S., Shakil, S., et al. (2014). Protein misfolding and aggregation in alzheimer’s disease and type 2 diabetes mellitus. CNS Neurol. Disord. Drug Targets 13 (7), 1280–1293. doi:10.2174/1871527313666140917095514

PubMed Abstract | CrossRef Full Text | Google Scholar

Atamna, H., Tenore, A., Lui, F., and Dhahbi, J. M. (2018). Organ reserve, excess metabolic capacity, and aging. Biogerontology 19 (2), 171–184. doi:10.1007/s10522-018-9746-8

PubMed Abstract | CrossRef Full Text | Google Scholar

Audouard, E., Van Hees, L., Suain, V., Yilmaz, Z., Poncelet, L., Leroy, K., et al. (2015). Motor deficit in a tauopathy model is induced by disturbances of axonal transport leading to dying-back degeneration and denervation of neuromuscular junctions. Am. J. Pathol. 185 (10), 2685–2697. doi:10.1016/j.ajpath.2015.06.011

PubMed Abstract | CrossRef Full Text | Google Scholar

Bakula, M. (1969). The persistence of a microbial flora during postembryogenesis of Drosophila melanogaster. J. Invertebr. Pathol. 14 (3), 365–374. doi:10.1016/0022-2011(69)90163-3

PubMed Abstract | CrossRef Full Text | Google Scholar

Bălaşa, A. F., Chircov, C., and Grumezescu, A. M. (2020). Body fluid biomarkers for alzheimer’s disease-an up-to-date overview. Biomedicines 8 (10), 421–21. doi:10.3390/biomedicines8100421

PubMed Abstract | CrossRef Full Text | Google Scholar

Barbut, D., Stolzenberg, E., and Zasloff, M. (2019). Gastrointestinal immunity and alpha-synuclein. J. Parkinson's Dis. 9 (2), S313–S322. doi:10.3233/JPD-191702

CrossRef Full Text | Google Scholar

Barnstedt, O., Owald, D., Felsenberg, J., Brain, R., Moszynski, J. P., Talbot, C. B., et al. (2016). Memory-relevant mushroom body output synapses are cholinergic. Neuron 89 (6), 1237–1247. doi:10.1016/j.neuron.2016.02.015

PubMed Abstract | CrossRef Full Text | Google Scholar

Baron, M. N., Klinger, C. M., Rachubinski, R. A., and Simmonds, A. J. (2016). A systematic cell-based analysis of localization of predicted Drosophila peroxisomal proteins. Traffic 17 (5), 536–553. doi:10.1111/tra.12384

PubMed Abstract | CrossRef Full Text | Google Scholar

Barrett, E. C., McBurney, M. I., and Ciappio, E. D. (2014). ω-3 fatty acid supplementation as a potential therapeutic aid for the recovery from mild traumatic brain injury/concussion. Adv. Nutr. 5 (3), 268–277. doi:10.3945/an.113.005280

PubMed Abstract | CrossRef Full Text | Google Scholar

Baxter, N. T., Schmidt, A. W., Venkataraman, A., Kim, K. S., Waldron, C., and Schmidt, T. M. (2019). Dynamics of human gut microbiota and short-chain fatty acids in response to dietary interventions with three fermentable fibers. MBio 10 (1), 025666-18. doi:10.1128/mBio.02566-18

CrossRef Full Text | Google Scholar

Bekris, L. M., Yu, C. E., Bird, T. D., and Tsuang, D. W. (2010). Genetics of alzheimer disease. J. Geriatr. psychiatry Neurol. 23 (4), 213–227. doi:10.1177/0891988710383571

PubMed Abstract | CrossRef Full Text | Google Scholar

Belkind-Gerson, J., Carreón-Rodríguez, A., Contreras-Ochoa, C. O., Estrada-Mondaca, S., Parra-Cabrera, M. S., and Carreon-Rodriguez, A. (2008). Fatty acids and neurodevelopment. J. Pediatr. Gastroenterol. Nutr. 47 (1), S7–S9. S7–S9. doi:10.1097/MPG.0b013e3181818e3f

PubMed Abstract | CrossRef Full Text | Google Scholar

Benskey, M. J., Perez, R. G., and Manfredsson, F. P. (2016). The contribution of alpha synuclein to neuronal survival and function - implications for Parkinson's disease. J. Neurochem. 137 (3), 331–359. doi:10.1111/jnc.13570

PubMed Abstract | CrossRef Full Text | Google Scholar

Berardelli, A., Rothwell, J. C., Thompson, P. D., and Hallett, M. (2001). Pathophysiology of bradykinesia in Parkinson's disease. J. Neurol. 124 (11), 2131–2146. doi:10.1093/brain/124.11.2131

PubMed Abstract | CrossRef Full Text | Google Scholar

Bercik, P., Park, A. J., Sinclair, D., Khoshdel, A., Lu, J., Huang, X., et al. (2011). The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication. Neurogastroenterol motil 23 (12), 1132–1139. doi:10.1111/j.1365-2982.2011.01796.x

PubMed Abstract | CrossRef Full Text | Google Scholar

Bernik, T. R., Friedman, S. G., Ochani, M., DiRaimo, R., Ulloa, L., Yang, H., et al. (2002). Pharmacological stimulation of the cholinergic antiinflammatory pathway. J. Exp. Med. 195 (6), 781–788. doi:10.1084/jem.20011714

PubMed Abstract | CrossRef Full Text | Google Scholar

Bolkan, B. J., and Kretzschmar, D. (2014). Loss of Tau results in defects in photoreceptor development and progressive neuronal degeneration in Drosophila. Dev. Neurobiol. 74 (12), 1210–1225. doi:10.1002/dneu.22199

PubMed Abstract | CrossRef Full Text | Google Scholar

Bologna, M., and Paparella, G. (2020). Neurodegeneration and sensorimotor function. Brain Sci. 10 (11), 808. doi:10.3390/brainsci10110808

PubMed Abstract | CrossRef Full Text | Google Scholar

Borovikova, L. V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G. I., Watkins, L. R., et al. (2000). Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405 (6785), 458–462. doi:10.1038/35013070

PubMed Abstract | CrossRef Full Text | Google Scholar

Bousquet, M., Gibrat, C., Saint-Pierre, M., Julien, C., Calon, F., and Cicchetti, F. (2009). Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model. Prog. Neuropsychopharmacol. Biol. Psychiatry 33 (8), 1401–1408. doi:10.1016/j.pnpbp.2009.07.018

PubMed Abstract | CrossRef Full Text | Google Scholar

Braak, H., Del Tredici, K., Rüb, U., De Vos, R. A. I., Jansen Steur, E. N. H., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24 (2), 197–211. doi:10.1016/S0197-4580(02)00065-9

PubMed Abstract | CrossRef Full Text | Google Scholar

Breit, S., Kupferberg, A., Rogler, G., and Hasler, G. (2018). Vagus nerve as modulator of the brain-gut axis in psychiatric and inflammatory disorders. Front. Psychiatry 9, 44. doi:10.3389/fpsyt.2018.00044

PubMed Abstract | CrossRef Full Text | Google Scholar

Brion, J. P., Smith, C., Couck, A. M., Gallo, J. M., and Anderton, B. H. (1993). Developmental changes in tau phosphorylation: Fetal tau is transiently phosphorylated in a manner similar to paired helical filament-tau characteristic of alzheimer's disease. J. Neurochem. 61 (6), 2071–2080. doi:10.1111/j.1471-4159.1993.tb07444.x

PubMed Abstract | CrossRef Full Text | Google Scholar

Broderick, N. A., Buchon, N., and Lemaitre, B. (2014). Microbiota-induced changes in Drosophila melanogaster host gene expression and gut morphology. mBio 5 (3), 011177–e1214. doi:10.1128/mBio.01117-14

PubMed Abstract | CrossRef Full Text | Google Scholar

Brooks, S. W., Dykes, A. C., and Schreurs, B. G. (2017). A high-cholesterol diet increases 27-hydroxycholesterol and modifies estrogen receptor expression and neurodegeneration in rabbit Hippocampus. J. Alzheimer's Dis. 56 (1), 185–196. doi:10.3233/JAD-160725

CrossRef Full Text | Google Scholar

Brudek, T. (2019). Inflammatory bowel diseases and Parkinson’s disease. J. Parkinson’s Dis. 9 (2), S331–S344. doi:10.3233/JPD-191729

CrossRef Full Text | Google Scholar

Buchanan, T. W., and Tranel, D. (2009). Central and peripheral nervous system interactions: From mind to brain to body. Int. J. Psychophysiol. 72 (1), 1–4. doi:10.1016/j.ijpsycho.2008.09.002

PubMed Abstract | CrossRef Full Text | Google Scholar

Cabin, D. E., Shimazu, K., Murphy, D., Cole, N. B., Gottschalk, W., McIlwain, K. L., et al. (2002). Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22 (20), 8797–8807. doi:10.1523/JNEUROSCI.22-20-08797.2002

PubMed Abstract | CrossRef Full Text | Google Scholar

Cai, D. (2013). Neuroinflammation and neurodegeneration in overnutrition-induced diseases. Trends Endocrinol. Metab. 24 (1), 40–47. doi:10.1016/j.tem.2012.11.003

PubMed Abstract | CrossRef Full Text | Google Scholar

Calon, F., and Cole, G. (2007). Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: Evidence from animal studies. Prostagl. Leukot. Essent. Fat. Acids 77 (5-6), 287–293. doi:10.1016/j.plefa.2007.10.019

PubMed Abstract | CrossRef Full Text | Google Scholar

Canfora, E. E., Jocken, J. W., and Blaak, E. E. (2015). Short-chain fatty acids in control of body weight and insulin sensitivity. Natur. Rev. Endocrinol. 11 (10), 577–591. doi:10.1038/nrendo.2015.128

PubMed Abstract | CrossRef Full Text | Google Scholar

Canning, D. R., McKeon, R. J., DeWitt, D. A., Perry, G., Wujek, J. R., Frederickson, R. C., et al. (1993). beta-Amyloid of Alzheimer's disease induces reactive gliosis that inhibits axonal outgrowth. Exp. Neurol. 124 (2), 289–298. doi:10.1006/exnr.1993.1199

PubMed Abstract | CrossRef Full Text | Google Scholar

Cao, Y., Chtarbanova, S., Petersen, A. J., and Ganetzky, B. (2013). Dnr1 mutations cause neurodegeneration in Drosophila by activating the innate immune response in the brain. Proc. Natl. Acad. Sci. U. S. A. 110 (19), E1752–E1760. doi:10.1073/pnas.1306220110

PubMed Abstract | CrossRef Full Text | Google Scholar

Capo, F., Wilson, A., and Di Cara, F. (2019). The intestine of Drosophila melanogaster: An emerging versatile model system to study intestinal epithelial homeostasis and host-microbial interactions in humans. Microorganisms 7 (9), 336. doi:10.3390/microorganisms7090336

PubMed Abstract | CrossRef Full Text | Google Scholar

Carabotti, M., Scirocco, A., Maselli, M. A., and Severi, C. (2015). The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. Ann. Gastroenterol. 28 (2), 203–209.

PubMed Abstract | Google Scholar

Cassim, J., Kolkman, F., and Helmer, M. (2018). Designs for flies + of mice and men: Design approaches to Drosophila melanogaster. Adv. Exp. Med. Biol. 1076, 289–305. doi:10.1007/978-981-13-0529-0_16

PubMed Abstract | CrossRef Full Text | Google Scholar

Castelli, V., d'Angelo, M., Quintiliani, M., Benedetti, E., Cifone, M. G., and Cimini, A. (2021). The emerging role of probiotics in neurodegenerative diseases: New hope for Parkinson's disease? Neural Regen. Res. 16 (4), 628–634. doi:10.4103/1673-5374.295270

PubMed Abstract | CrossRef Full Text | Google Scholar

Castillo-Armengol, J., Fajas, L., and Lopez-Mejia, I. C. (2019). Inter-organ communication: A gatekeeper for metabolic health. EMBO Rep. 20 (9), e47903. doi:10.15252/embr.201947903

PubMed Abstract | CrossRef Full Text | Google Scholar

Cena, H., and Calder, P. C. (2020). Defining a healthy diet: Evidence for the role of. Nutrients 12 (334), 1–15. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071223/pdf/nutrients-12-00334.pdf.

CrossRef Full Text | Google Scholar

Chalazonitis, A., and Rao, M. (2018). Enteric nervous system manifestations of neurodegenerative disease. Brain Res. 1693, 207–213. doi:10.1016/j.brainres.2018.01.011

PubMed Abstract | CrossRef Full Text | Google Scholar

Challis, C., Hori, A., Sampson, T. R., Yoo, B. B., Challis, R. C., Hamilton, A. M., et al. (2020). Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice. Nat. Neurosci. 23 (3), 327–336. doi:10.1038/s41593-020-0589-7

PubMed Abstract | CrossRef Full Text | Google Scholar

Chandler, J. A., Lang, J. M., Bhatnagar, S., Eisen, J. A., and Kopp, A. (2011). Bacterial communities of diverse Drosophila species: Ecological context of a host-microbe model system. PLoS Genet. 7 (9), e1002272. doi:10.1371/journal.pgen.1002272

PubMed Abstract | CrossRef Full Text | Google Scholar

Chang, Y. T., Chang, W. N., Tsai, N. W., Huang, C. C., Kung, C. T., Su, Y. J., et al. (2014). The roles of biomarkers of oxidative stress and antioxidant in alzheimer's disease: A systematic review. Biomed. Res. Int. 2014, 182303. doi:10.1155/2014/182303

PubMed Abstract | CrossRef Full Text | Google Scholar

Chaston, J. M., Newell, P. D., and Douglas, A. E. (2014). Metagenome-wide association of microbial determinants of host phenotype in Drosophila melanogaster. mBio 5 (5), 016311–e1714. doi:10.1128/mBio.01631-14

PubMed Abstract | CrossRef Full Text | Google Scholar

Chatelier, E. L., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., et al. (2013). Richness of human gut microbiome correlates with metabolic markers. Nature 500 (7464), 541–546. doi:10.1038/nature12506

PubMed Abstract | CrossRef Full Text | Google Scholar

Chen, G. F., Xu, T. H., Yan, Y., Zhou, Y. R., Jiang, Y., Melcher, K., et al. (2017). Amyloid beta: Structure, biology and structure-based therapeutic development. Acta Pharmacol. Sin. 38 (9), 1205–1235. doi:10.1038/aps.2017.28

PubMed Abstract | CrossRef Full Text | Google Scholar

Chen, H., Meng, L., and Shen, L. (2022). Multiple roles of short-chain fatty acids in Alzheimer disease. Nutrition 93, 111499. doi:10.1016/j.nut.2021.111499

PubMed Abstract | CrossRef Full Text | Google Scholar

Chen, Q. Q., Haikal, C., Li, W., and Li, J. Y. (2019). Gut inflammation in association with pathogenesis of Parkinson’s disease. Front. Mol. Neurosci. 1, 218. –13. doi:10.3389/fnmol.2019.00218

CrossRef Full Text | Google Scholar

Chen, S. G., Stribinskis, V., Rane, M. J., Demuth, D. R., Gozal, E., Roberts, A. M., et al. (2016). Exposure to the functional bacterial amyloid protein curli enhances alpha-synuclein aggregation in aged fischer 344 rats and Caenorhabditis elegans. Sci. Rep. 6, 34477. doi:10.1038/srep34477

PubMed Abstract | CrossRef Full Text | Google Scholar

Chianese, R., Coccurello, R., Viggiano, A., Scafuro, M., Fiore, M., Coppola, G., et al. (2018). Impact of dietary fats on brain functions. Cur Neuropharmacol. 16 (7), 1059–1085. doi:10.2174/1570159X15666171017102547

PubMed Abstract | CrossRef Full Text | Google Scholar

Christ, A., Lauterbach, M., and Latz, E. (2019). Western diet and the immune system: An inflammatory connection. Immunity 51 (5), 794–811. doi:10.1016/j.immuni.2019.09.020

PubMed Abstract | CrossRef Full Text | Google Scholar

Cipolla, C. M., and Lodhi, I. J. (2017). Peroxisomal dysfunction in age-related diseases. Trends Endocrinol. Metab. 28 (4), 297–308. doi:10.1016/j.tem.2016.12.003

PubMed Abstract | CrossRef Full Text | Google Scholar

Clancy, B. (2013). Developmental science and executive function. Curr. Dir. Psychol. Sci. 1 (25), 3–7. doi:10.1177/0963721415622634

CrossRef Full Text | Google Scholar

Clark, R. I., Salazar, A., Yamada, R., Fitz-Gibbon, S., Morselli, M., Alcaraz, J., et al. (2015). Distinct shifts in microbiota composition during Drosophila aging impair intestinal function and drive mortality. Cell Rep. 12 (10), 1656–1667. doi:10.1016/j.celrep.2015.08.004

PubMed Abstract | CrossRef Full Text | Google Scholar

Console, L., Scalise, M., Giangregorio, N., Tonazzi, A., Barile, M., and Indiveri, C. (2020). The link between the mitochondrial fatty acid oxidation derangement and kidney injury. Front. Physiol. 11, 794–797. doi:10.3389/fphys.2020.00794

PubMed Abstract | CrossRef Full Text | Google Scholar

Coon, E. A., and Singer, W. (2020). Synucleinopathies. Contin. Minneap. Minn. 26 (1), 72–92. doi:10.1212/CON.0000000000000819

PubMed Abstract | CrossRef Full Text | Google Scholar

Corby-Harris, V., Pontaroli, A. C., Shimkets, L. J., Bennetzen, J. L., Habel, K. E., and Promislow, D. E. (2007). Geographical distribution and diversity of bacteria associated with natural populations of Drosophila melanogaster. Appl. Environ. Microbiol. 73 (11), 3470–3479. doi:10.1128/AEM.02120-06

PubMed Abstract | CrossRef Full Text | Google Scholar

Cording, A. C., Shiaelis, N., Petridi, S., Middleton, C. A., Wilson, L. G., and Elliott, C. J. H. (2017). Targeted kinase inhibition relieves slowness and tremor in a Drosophila model of LRRK2 Parkinson's disease. NPJ Parkinson's Dis. 3, 34. doi:10.1038/s41531-017-0036-y

PubMed Abstract | CrossRef Full Text | Google Scholar

Cotillard, A., Kennedy, S. P., Kong, L. C., Prifti, E., Pons, N., Le Chatelier, E., et al. (2013). Dietary intervention impact on gut microbial gene richness. Nature 500 (7464), 585–588. doi:10.1038/nature12480

PubMed Abstract | CrossRef Full Text | Google Scholar

Cranston, A. L., Wysocka, A., Steczkowska, M., Zadrożny, M., Palasz, E., Harrington, C. R., et al. (2020). Cholinergic and inflammatory phenotypes in transgenic tau mouse models of Alzheimer's disease and frontotemporal lobar degeneration. Brain Commun. 2 (1), fcaa033. doi:10.1093/braincomms/fcaa033

PubMed Abstract | CrossRef Full Text | Google Scholar

Custers, , Emma, E. M., Kiliaan, , and Amanda, J. (2022). Dietary lipids from body to brain. Prog. Lipid Res. 101144, 101144. doi:10.1016/j.plipres.2021.101144

PubMed Abstract | CrossRef Full Text | Google Scholar

Da Costa, R. Q. M., de Gobbi Porto, F. H., and Paysano Marrocos, R. (2013). Dissociation of depression from apathy in traumatic brain injury: A case report. Dement. Neuropsychol. 7 (3), 312–315. doi:10.1590/S1980-57642013DN70300014

PubMed Abstract | CrossRef Full Text | Google Scholar

Daneman, R., and Prat, A. (2015). The blood-brain barrier. CSH Perspect. Biol. 7 (1), a020412. doi:10.1101/cshperspect.a020412

PubMed Abstract | CrossRef Full Text | Google Scholar

Das, P., Babaei, P., and Nielsen, J. (2019). Metagenomic analysis of microbe-mediated vitamin metabolism in the human gut microbiome. BMC Genomics 20, 208. doi:10.1186/s12864-019-5591-7

PubMed Abstract | CrossRef Full Text | Google Scholar

Dawson, T. M., Golde, T. E., and Lagier-Tourenne, C. (2018). Animal models of neurodegenerative diseases. Nat. Neurosci. 21 (10), 1370–1379. doi:10.1038/s41593-018-0236-8

PubMed Abstract | CrossRef Full Text | Google Scholar

de Wouters d’Oplinter, A., Rastelli, M., Van Hul, M., Delzenne, N. M., Cani, P. D., and Everard, A. (2021). Gut microbes participate in food preference alterations during obesity. Gut Microbe 13 (1), 1959242. doi:10.1080/19490976.2021.1959242

CrossRef Full Text | Google Scholar

Dehmelt, L., and Halpain, S. (2005). The MAP2/Tau family of microtubule-associated proteins. Genome Biol. 6 (1), 204. doi:10.1186/gb-2004-6-1-204

PubMed Abstract | CrossRef Full Text | Google Scholar

Derkinderen, P., Rolli-Derkinderen, M., Chapelet, G., Neunlist, M., and Noble, W. (2021). Tau in the gut, does it really matter? J. Neurochem. 158 (2), 94–104. doi:10.1111/jnc.15320

PubMed Abstract | CrossRef Full Text | Google Scholar

Desbonnet, L., Garrett, L., Clarke, G., Bienenstock, J., and Dinan, T. G. (2008). The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat. J. Psychiatr. Res. 43 (2), 164–174. doi:10.1016/j.jpsychires.2008.03.009

PubMed Abstract | CrossRef Full Text | Google Scholar

Devos, D., Lebouvier, T., Lardeux, B., Biraud, M., Rouaud, T., Pouclet, H., et al. (2013). Colonic inflammation in Parkinson's disease. Neurobiol. Dis. 50, 42–48. doi:10.1016/j.nbd.2012.09.007

PubMed Abstract | CrossRef Full Text | Google Scholar

Di Cara, F., Bülow, M. H., Simmonds, A. J., and Rachubinski, R. A. (2018). Dysfunctional peroxisomes compromise gut structure and host defense by increased cell death and Tor-dependent autophagy. Mol. Biol. Cell 29 (22), 2766–2783. doi:10.1091/mbc.E18-07-0434

PubMed Abstract | CrossRef Full Text | Google Scholar

Di Cara, F. (2020). Peroxisomes in host defense. PLoS Pathog. 16 (7), 10086366–e1008710. doi:10.1371/journal.ppat.1008636

CrossRef Full Text | Google Scholar

Dijkstra, A. A., Voorn, P., Berendse, H. W., Groenewegen, H. J., Rozemuller, A. J., and van de Berg, W. D. (2014). Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease. Mov. Disord. 29 (10), 1244–1251. doi:10.1002/mds.25952

PubMed Abstract | CrossRef Full Text | Google Scholar

Dinan, T. G., and Cryan, J. F. (2017). Gut instincts: Microbiota as a key regulator of brain development, ageing and neurodegeneration. J. Physiol. 595 (2), 489–503. doi:10.1113/JP273106

PubMed Abstract | CrossRef Full Text | Google Scholar

Dinan, T. G., and Cryan, J. F. (2015). The impact of gut microbiota on brain and behaviour: Implications for psychiatry. Curr. Opin. Clin. Nutr. metabolic care 18 (6), 552–558. doi:10.1097/MCO.0000000000000221

PubMed Abstract | CrossRef Full Text | Google Scholar

Dorsey, E. R., Sherer, T., Okun, M. S., and Bloemd, B. R. (2018). The emerging evidence of the Parkinson pandemic. J. Parkinson’s Dis. 8 (1), S3–S8. doi:10.3233/JPD-181474

CrossRef Full Text | Google Scholar

Douglas, A. E. (2018). The Drosophila model for microbiome research. Lab. Anim. 47 (6), 157–164. doi:10.1038/s41684-018-0065-0

PubMed Abstract | CrossRef Full Text | Google Scholar

Driver-Dunckley, E., Adler, C. H., Hentz, J. G., Dugger, B. N., Shill, H. A., Caviness, J. N., et al. (2014). Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease. Park. Relat. Disord. 20 (11), 1260–1262. Epub 2014 Aug 16. PMID: 25172126; PMCID: PMC4835172. doi:10.1016/j.parkreldis.2014.08.006

PubMed Abstract | CrossRef Full Text | Google Scholar

Dugger, B. N., Perl, D. P., and Carlson, G. A. (2017). Neurodegenerative disease transmission and transgenesis in mice. Cold Spring Harb. Perspect. Biol. 9 (11), a023549. doi:10.1101/cshperspect.a023549

PubMed Abstract | CrossRef Full Text | Google Scholar

Durães, F., Pinto, M., and Sousa, E. (2018). Old drugs as new treatments for neurodegenerative diseases. Pharmaceuticals 11 (2), 44–21. doi:10.3390/ph11020044

PubMed Abstract | CrossRef Full Text | Google Scholar

Engelhardt, E. (2017). Lafora and trétiakoff: The naming of the inclusion bodies discovered by Lewy. Arq. neuro-psiquiatria 75 (10), 751–753. doi:10.1590/0004-282X20170116

PubMed Abstract | CrossRef Full Text | Google Scholar

Erkkinen, M. G., Kim, M. O., and Geschwind, M. D. (2018). Clinical neurology and epidemiology of the major neurodegenerative diseases. CHS 10 (4), a033118. doi:10.1101/cshperspect.a033118

PubMed Abstract | CrossRef Full Text | Google Scholar

Erkosar, B., Storelli, G., Defaye, A., and Leulier, F. (2013). Host-intestinal microbiota mutualism: "learning on the fly. Cell host microbe 13 (1), 8–14. doi:10.1016/j.chom.2012.12.004

PubMed Abstract | CrossRef Full Text | Google Scholar

Erny, D., Hrabě de Angelis, A. L., Jaitin, D., Wieghofer, P., Staszewski, O., David, E., et al. (2015). Host microbiota constantly control maturation and function of microglia in the CNS. Nat. Neurosci. 18 (7), 965–977. doi:10.1038/nn.4030

PubMed Abstract | CrossRef Full Text | Google Scholar

Faustini, G., Bono, F., Valerio, A., Pizzi, M., Spano, P., and Bellucci, A. (2017). Mitochondria and α-synuclein: Friends or foes in the pathogenesis of Parkinson’s disease? Genes 8 (12), 377–379. doi:10.3390/genes8120377

PubMed Abstract | CrossRef Full Text | Google Scholar

Feany, M. B., and Bender, W. W. (2000). A Drosophila model of Parkinson's disease. Nature 404 (6776), 394–398. doi:10.1038/35006074

PubMed Abstract | CrossRef Full Text | Google Scholar

Fedele, G., Loh, S., Celardo, I., Lehmann, S., Costa, A., and Martins, L. M. (2022). Suppression of intestinal dysfunction in a Drosophila model of Parkinson’s disease is neuroprotective nature research. Nature Aging 2 (4), 1–15. doi:10.1038/s43587-022-00194-z

CrossRef Full Text | Google Scholar

Fedele, G., Loh, S. H. Y., Celardo, I., Leal, S. N., Lehmann, S., Costa, A. C., et al. (2022). Suppression of intestinal dysfunction in a Drosophila model of Parkinson’s disease is neuroprotective. Nat. Aging 2, 317–331. doi:10.1038/s43587-022-00194-z

CrossRef Full Text | Google Scholar

Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., et al. (2019). Global, regional, and national burden of neurological disorders, 1990–2016: A systematic analysis for the global burden of disease study 2016. Lancet Neurol. 18 (5), 459–480. doi:10.1016/S1474-4422(18)30499-X

PubMed Abstract | CrossRef Full Text | Google Scholar

Feigin, V. L., Vos, T., Nichols, E., Owolabi, M. O., Carroll, W. M., Dichgans, M., et al. (2020). The global burden of neurological disorders: Translating evidence into policy. Lancet Neurol. 19 (3), 255–265. doi:10.1016/S1474-4422(19)30411-9

PubMed Abstract | CrossRef Full Text | Google Scholar

Festi, D., Schiumerini, R., Eusebi, L. H., Marasco, G., Taddia, M., and Colecchia, A. (2014). Gut microbiota and metabolic syndrome. World J. Gastroenterol. 20 (43), 16079–16094. doi:10.3748/wjg.v20.i43.16079

PubMed Abstract | CrossRef Full Text | Google Scholar

Fischer, C. N., Trautman, E. P., Crawford, J. M., Stabb, E. V., Handelsman, J., and Broderick, N. A. (2017). Metabolite exchange between microbiome members produces compounds that influence Drosophila behavior. eLife 6, e18855. doi:10.7554/eLife.18855

PubMed Abstract | CrossRef Full Text | Google Scholar

Fleming, M. A., Ehsan, L., Moore, S. R., and Levin, D. E. (2020). The enteric nervous system and its emerging role as a therapeutic target. Gastroenterol. Res. Pract. 2020, 8024171. doi:10.1155/2020/8024171

PubMed Abstract | CrossRef Full Text | Google Scholar

Fossgreen, A., Brückner, B., Czech, C., Masters, C. L., Beyreuther, K., and Paro, R. (1998). Transgenic Drosophila expressing human amyloid precursor protein show gamma-secretase activity and a blistered-wing phenotype. Proc. Natl. Acad. Sci. U. S. A. 95 (23), 13703–13708. doi:10.1073/pnas.95.23.13703

PubMed Abstract | CrossRef Full Text | Google Scholar

Friedland, R. P. (2015). Mechanisms of molecular mimicry involving the microbiota in neurodegeneration. J. Alzheimer's Dis. 45 (2), 349–362. doi:10.3233/JAD-142841

PubMed Abstract | CrossRef Full Text | Google Scholar

Friedman, J. R., and Nunnari, J. (2014). Mitochondrial form and function. Nature 505 (7483), 335–343. doi:10.1038/nature12985

PubMed Abstract | CrossRef Full Text | Google Scholar

Fu, H., Rodriguez, G. A., Herman, M., Emrani, S., Nahmani, E., Barrett, G., et al. (2017). Tau pathology induces excitatory neuron loss, grid cell dysfunction, and spatial memory deficits reminiscent of early alzheimer's disease. Neuron 93 (3), 533–541. doi:10.1016/j.neuron.2016.12.023

PubMed Abstract | CrossRef Full Text | Google Scholar

Galland, L. (2014). The gut microbiome and the brain. J. Med. Food 17 (12), 1261–1272. doi:10.1089/jmf.2014.7000

PubMed Abstract | CrossRef Full Text | Google Scholar

Galloway, S., Jian, L., Johnsen, R., Chew, S., and Mamo, J. C. (2007). beta-amyloid or its precursor protein is found in epithelial cells of the small intestine and is stimulated by high-fat feeding. Phys. Act. Nutr. Biochem. 18 (4), 279–284. doi:10.1016/j.jnutbio.2006.07.003

PubMed Abstract | CrossRef Full Text | Google Scholar

Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., et al. (1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373 (6514), 523–527. doi:10.1038/373523a0

PubMed Abstract | CrossRef Full Text | Google Scholar

Garden, G. A., and La Spada, A. R. (2012). Intercellular (mis)communication in neurodegenerative disease. Neuron 73 (5), 886–901. doi:10.1016/j.neuron.2012.02.017

PubMed Abstract | CrossRef Full Text | Google Scholar

Gehrke, S., Imai, Y., Sokol, N., and Lu, B. (2010). Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466 (7306), 637–641. doi:10.1038/nature09191

PubMed Abstract | CrossRef Full Text | Google Scholar

Gkouskou, K. K., Deligianni, C., Tsatsanis, C., and Eliopoulos, A. G. (2014). The gut microbiota in mouse models of inflammatory bowel disease. Front. Cell Infect. Microbiol. 4 (28), 28. doi:10.3389/fcimb.2014.00028

PubMed Abstract | CrossRef Full Text | Google Scholar

Gomez-Marin, A., Oron, E., Gakamsky, A., Valente, D., Benjamini, Y., and Golani, I. (2016). Generative rules of Drosophila locomotor behavior as a candidate homology across phyla. Sci. Rep. 6 (27555), 27555. doi:10.1038/srep27555

PubMed Abstract | CrossRef Full Text | Google Scholar

Goverse, G., Stakenborg, M., and Matteoli, G. (2016). The intestinal cholinergic anti-inflammatory pathway. J. Physiol. 594 (20), 5771–5780. doi:10.1113/JP271537

PubMed Abstract | CrossRef Full Text | Google Scholar

Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., et al. (1995). Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J. Biol. Chem. 270 (13), 7013–7016. doi:10.1074/jbc.270.13.7013

PubMed Abstract | CrossRef Full Text | Google Scholar

Gray, M. T., and Woulfe, J. M. (2015). Striatal blood-brain barrier permeability in Parkinson's disease. J. Cereb. Blood Flow. Metab. 35 (5), 747–750. doi:10.1038/jcbfm.2015.32

PubMed Abstract | CrossRef Full Text | Google Scholar

Growdon, J. H., Kieburtz, K., McDermott, M. P., Panisset, M., and Friedman, J. H. (1998). Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group. Neurology 50 (5), 1327–1331. doi:10.1212/wnl.50.5.1327

PubMed Abstract | CrossRef Full Text | Google Scholar

Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., and Binder, L. I. (1986). Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 83 (13), 4913–4917. doi:10.1073/pnas.83.13.4913

PubMed Abstract | CrossRef Full Text | Google Scholar

Guillot-Sestier, M. V., and Town, T. (2018). Let's make microglia great again in neurodegenerative disorders. J. neural Transm. 125 (5), 751–770. doi:10.1007/s00702-017-1792-x

PubMed Abstract | CrossRef Full Text | Google Scholar

Guo, S., Al-Sadi, R., Said, H. M., and Ma, T. Y. (2013). Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. An J pathol 182 (2), 375–387. doi:10.1016/j.ajpath.2012.10.014

PubMed Abstract | CrossRef Full Text | Google Scholar

Gustafsson, B. (1946). Germ-free rearing of rats. Acta anat. 2 (3-4), 376–391. doi:10.1159/000140222

PubMed Abstract | CrossRef Full Text | Google Scholar

Hakansson, A., and Molin, G. (2011). Gut microbiota and inflammation. Nutrients 3 (6), 637–682. doi:10.3390/nu3060637

PubMed Abstract | CrossRef Full Text | Google Scholar

Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., et al. (2021). The amyloid-β pathway in alzheimer’s disease. Mol. Psychiatry 26 (10), 5481–5503. doi:10.1038/s41380-021-01249-0

PubMed Abstract | CrossRef Full Text | Google Scholar

Hanson, M. A., and Lemaitre, B. (2022). Antimicrobial peptides do not directly contribute to aging in Drosophila, but improve lifespan by preventing dysbiosis. BioRxiv 24, 504952. doi:10.1101/2022.08.24.504952

CrossRef Full Text | Google Scholar

Harach, T., Marungruang, N., Duthilleul, N., Cheatham, V., Mc Coy, K. D., Neher, J. J., et al. (2015). Reduction of beta-amyloid pathology in the absence of gut microbiota. doi:10.48550/arXiv.1509.02273

CrossRef Full Text | Google Scholar

Harada, A., Oguchi, K., Okabe, S., Kuno, J., Terada, S., Ohshima, T., et al. (1994). Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369 (6480), 488–491. doi:10.1038/369488a0

PubMed Abstract | CrossRef Full Text | Google Scholar

Harris, M., Hulseberg, P., Ling, C., Karman, J., Clarkson, B. D., Harding, S. J., et al. (2014). Immune privilege of the CNS is not the consequence of limited antigen sampling. Sci. Rep. 4, 4422. doi:10.1038/srep04422

PubMed Abstract | CrossRef Full Text | Google Scholar

Hasegawa, K., Stoessl, A. J., Yokoyama, T., Kowa, H., Wszolek, Z. K., and Yagishita, S. (2009). Familial parkinsonism: Study of original sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Park. Relat. Disord. 15 (4), 300–306. doi:10.1016/j.parkreldis.2008.07.010

PubMed Abstract | CrossRef Full Text | Google Scholar

Hawkes, C. H., Del Tredici, K., and Braak, H. (2010). A timeline for Parkinson's disease. Park Relat. Disord. 16 (2), 79–84. doi:10.1016/j.parkreldis.2009.08.007

PubMed Abstract | CrossRef Full Text | Google Scholar

Heidary, G., and Fortini, M. E. (2001). Identification and characterization of the Drosophila tau homolog. Mech. Dev. 108 (1-2), 171–178. doi:10.1016/s0925-4773(01)00487-7

PubMed Abstract | CrossRef Full Text | Google Scholar

Hernández, F., Merchán-Rubira, J., Vallés-Saiz, L., Rodríguez-Matellán, A., and Avila, J. (2020). Differences between human and murine tau at the N-terminal end. Front. aging Neurosci. 12, 11. doi:10.3389/fnagi.2020.00011

PubMed Abstract | CrossRef Full Text | Google Scholar

Hetz, C., and Saxena, S. (2017). ER stress and the unfolded protein response in neurodegeneration. Neurology 13 (8), 477–491. doi:10.1038/nrneurol.2017.99

PubMed Abstract | CrossRef Full Text | Google Scholar

Hickman, S., Izzy, S., Sen, P., Morsett, L., and El Khoury, J. (2018). Microglia in neurodegeneration. Nat. Neurosci. 21 (10), 1359–1369. doi:10.1038/s41593-018-0242-x

PubMed Abstract | CrossRef Full Text | Google Scholar

Hilton, D., Stephens, M., Kirk, L., Edwards, P., Potter, R., Zajicek, J., et al. (2014). Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson's disease. Acta Neuropathol. 127 (2), 235–241. Epub 2013 Nov 17. PMID: 24240814. doi:10.1007/s00401-013-1214-6

PubMed Abstract | CrossRef Full Text | Google Scholar

Ho, W. L., Leung, Y., Tsang, A. W., So, K. F., Chiu, K., and Chang, R. C. C. (2012). Review: Tauopathy in the retina and optic nerve: Does it shadow pathological changes in the brain? Molec Vis. 18, 2700–2710.

PubMed Abstract | Google Scholar

Hoffmann, J. A., and Reichhart, J. M. (2002). Drosophila innate immunity: An evolutionary perspective. Nat. Immunol. 3 (2), 121–126. doi:10.1038/ni0202-121

PubMed Abstract | CrossRef Full Text | Google Scholar

Hoffmann, J. A. (2003). The immune response of Drosophila. Nature 426 (6962), 33–38. doi:10.1038/nature02021

PubMed Abstract | CrossRef Full Text | Google Scholar

Hofmann, J. P., Denner, P., Nussbaum-Krammer, C., Kuhn, P. H., Suhre, M. H., Scheibel, T., et al. (2013). Cell-to-cell propagation of infectious cytosolic protein aggregates. PNAS 110 (15), 5951–5956. doi:10.1073/pnas.1217321110

PubMed Abstract | CrossRef Full Text | Google Scholar

Holmqvist, S., Chutna, O., Bousset, L., Aldrin-Kirk, P., Li, W., Björklund, T., et al. (2014). Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta neuropathol. 128 (6), 805–820. doi:10.1007/s00401-014-1343-6

PubMed Abstract | CrossRef Full Text | Google Scholar

Howland, R. H. (2014). Vagus nerve stimulation. Curr. Behav. Neurosci. Rep. 1 (2), 64–73. doi:10.1007/s40473-014-0010-5

PubMed Abstract | CrossRef Full Text | Google Scholar

Huang, Y., Wang, G., Rowe, D., Wang, Y., Kwok, J. B. J., Xiao, Q., et al. (2015). SNCA gene, but not MAPT, influences onset age of Parkinson’s disease in Chinese and Australians. Biomed. Res. Int. 2015, 135674. doi:10.1155/2015/135674

PubMed Abstract | CrossRef Full Text | Google Scholar

Hui, K. Y., Fernandez-Hernandez, H., Hu, J., Schaffner, A., Pankratz, N., Hsu, N. Y., et al. (2018). Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease. Sci. transla Med. 10 (423), eaai7795. doi:10.1126/scitranslmed.aai7795

PubMed Abstract | CrossRef Full Text | Google Scholar

Hung, R. J., Hu, Y., Kirchner, R., Liu, Y., Xu, C., Comjean, A., et al. (2020). A cell atlas of the adult Drosophila midgut. Proc. Natl. Acad. Sci. U. S. A. 117 (3), 1514–1523. doi:10.1073/pnas.1916820117

PubMed Abstract | CrossRef Full Text | Google Scholar

Hussain, B., Fang, C., and Chang, J. (2021). Blood-brain barrier breakdown: An emerging biomarker of cognitive impairment in normal aging and dementia. Front. Neurosci. 15, 688090. doi:10.3389/fnins.2021.688090

PubMed Abstract | CrossRef Full Text | Google Scholar

Iijima, K., Liu, H. P., Chiang, A. S., Hearn, S. A., Konsolaki, M., and Zhong, Y. (2004). Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: A potential model for alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 101 (17), 6623–6628. doi:10.1073/pnas.0400895101

PubMed Abstract | CrossRef Full Text | Google Scholar

Ikeda, M., Brown, J., Holland, A. J., Fukuhara, R., and Hodges, J. R. (2002). Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry Res. 73 (4), 371–376. doi:10.1136/jnnp.73.4.371

PubMed Abstract | CrossRef Full Text | Google Scholar

Innis, S. M. (2008). Dietary omega 3 fatty acids and the developing brain. Brain Res. 1237, 35–43. doi:10.1016/j.brainres.2008.08.078

PubMed Abstract | CrossRef Full Text | Google Scholar

Iqbal, K., Liu, F., Gong, C. X., and Grundke-Iqbal, I. (2010). Tau in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 7 (8), 656–664. doi:10.2174/156720510793611592

PubMed Abstract | CrossRef Full Text | Google Scholar

Iranzo, A., Gelpi, E., Tolosa, E., Molinuevo, J. L., Serradell, M., Gaig, C., et al. (2014). Neuropathology of prodromal Lewy body disease. Mov. Disord. 29 (3), 410–415. doi:10.1002/mds.25825

PubMed Abstract | CrossRef Full Text | Google Scholar

Itoh, H., Ueda, M., Suzuki, M., and Kohmura-Kobayashi, Y. (2022). Developmental origins of metaflammation; A bridge to the future between the DOHaD theory and evolutionary biology. Front. Endocrinol. 13, 839436. doi:10.3389/fendo.2022.839436

CrossRef Full Text | Google Scholar

Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., et al. (2009). Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139 (3), 485–498. doi:10.1016/j.cell.2009.09.033

PubMed Abstract | CrossRef Full Text | Google Scholar

Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., and Ihara, Y. (1994). Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43). Neuron 13 (1), 45–53. doi:10.1016/0896-6273(94)90458-8

PubMed Abstract | CrossRef Full Text | Google Scholar

Jackson, D. N., and Theiss, A. L. (2020). Gut bacteria signaling to mitochondria in intestinal inflammation and cancer. Gut microbe 11 (3), 285–304. doi:10.1080/19490976.2019.1592421

PubMed Abstract | CrossRef Full Text | Google Scholar

Jahn, H. (2013). Memory loss in Alzheimer's disease. Dialogues Clin. Neurosci. 15 (4), 445–454. doi:10.31887/DCNS.2013.15.4/hjahn

PubMed Abstract | CrossRef Full Text | Google Scholar

Jahromi, S. R., Ramesh, S. R., Finkelstein, D. L., and Haddadi, M. (2020). SNCAE46K transgenic Drosophila model of Parkinson’s disease confirmed the causative role of oxidative stress. CSH bioTxiv. doi:10.1101/2020.02.28.969501

CrossRef Full Text | Google Scholar

Jeibmann, A., and Paulus, W. (2009). Drosophila melanogaster as a model organism of brain diseases. Int. J. Mol. Sci. I (2), 407–440. doi:10.3390/ijms10020407

PubMed Abstract | CrossRef Full Text | Google Scholar

Jia, H., Li, X., Gao, H., Feng, Z., Li, X., Zhao, L., et al. (2008). High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease. J. Neurosci. Res. 86 (9), 2083–2090. doi:10.1002/jnr.21650

PubMed Abstract | CrossRef Full Text | Google Scholar

Jiao, S. S., Shen, L. L., Zhu, C., Bu, X. L., Liu, Y. H., Liu, C. H., et al. (2016). Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer's disease. Transl. psychiatry 6 (10), e907. doi:10.1038/tp.2016.186

PubMed Abstract | CrossRef Full Text | Google Scholar

Joachim, C. L., Mori, H., and Selkoe, D. J. (1989). Amyloid beta-protein deposition in tissues other than brain in Alzheimer's disease. Nature 341 (6239), 226–230. doi:10.1038/341226a0

PubMed Abstract | CrossRef Full Text | Google Scholar

Johannsen, D. L., and Ravussin, E. (2009). The role of mitochondria in health and disease. Curr. Opin. Pharmacol. 9 (6), 780–786. doi:10.1016/j.coph.2009.09.002

PubMed Abstract | CrossRef Full Text | Google Scholar

Jones, M. K., Nair, A., and Gupta, M. (2019). Mast cells in neurodegenerative disease. Front. Cell Neurosci. 13 (171), 171. doi:10.3389/fncel.2019.00171

PubMed Abstract | CrossRef Full Text | Google Scholar

Ju, Y. E. S., McLeland, J. S., Toedebusch, C. D., Xiong, C., Fagan, A. M., Duntley, S. P., et al. (2013). Sleep quality and preclinical alzheimer disease. JAMA Neurol. 70 (5), 587–593. doi:10.1001/jamaneurol.2013.2334

PubMed Abstract | CrossRef Full Text | Google Scholar

Just, S., Mondot, S., Ecker, J., Wegner, K., Rath, E., Gau, L., et al. (2018). The gut microbiota drives the impact of bile acids and fat source in diet on mouse metabolism. Microbiome 6 (1), 134. doi:10.1186/s40168-018-0510-8

PubMed Abstract | CrossRef Full Text | Google Scholar

Jyothi, H. J., Vidyadhara, D. J., Mahadevan, A., Philip, M., Parmar, S. K., Manohari, S. G., et al. (2015). Aging causes morphological alterations in astrocytes and microglia in human substantia nigra pars compacta. Neurobiol. aging 36 (12), 3321–3333. doi:10.1016/j.neurobiolaging.2015.08.024

PubMed Abstract | CrossRef Full Text | Google Scholar

Kaasinen, V., Joutsa, J., Noponen, T., and Päivärinta, M. (2014). Akinetic crisis in Parkinson's disease is associated with a severe loss of striatal dopamine transporter function: A report of two cases. Case Rep. neurology 6 (3), 275–280. doi:10.1159/000369448

PubMed Abstract | CrossRef Full Text | Google Scholar

Kabouridis, P. S., and Pachnis, V. (2015). Emerging roles of gut microbiota and the immune system in the development of the enteric nervous system. J. Clin Invest. 125 (3), 956–964. doi:10.1172/JCI76308

PubMed Abstract | CrossRef Full Text | Google Scholar

Kamareddine, L., Robins, W. P., Berkey, C. D., Mekalanos, J. J., and Watnick, P. I. (2018). The Drosophila immune deficiency pathway modulates enteroendocrine function and host metabolism. Cell Metab. 28 (3), 449–462. doi:10.1016/j.cmet.2018.05.026

PubMed Abstract | CrossRef Full Text | Google Scholar

Kametani, F., and Hasegawa, M. (2018). Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer’s disease. Front. Neurosci. 12, 25. doi:10.3389/fnins.2018.00025

PubMed Abstract | CrossRef Full Text | Google Scholar

Kamp, F., Exner, N., Lutz, A. K., Wender, N., Hegermann, J., Brunner, B., et al. (2010). Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J. 29 (20), 3571–3589. doi:10.1038/emboj.2010.223

PubMed Abstract | CrossRef Full Text | Google Scholar

Kang, L., Wu, K. P., Vendruscolo, M., and Baum, J. (2011). The A53T mutation is key in defining the differences in the aggregation kinetics of human and mouse α-synuclein. J An Chem 133 (34), 13465–13470. doi:10.1021/ja203979j

PubMed Abstract | CrossRef Full Text | Google Scholar

Kassebaum, J. N. (2022). Global, regional, and national burden of diseases and injuries for adults 70 years and older: Systematic analysis for the global burden of disease 2019 study. BMJ 376, 376. doi:10.1136/bmj-2021-068208

CrossRef Full Text | Google Scholar

Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., et al. (2015). Colonic bacterial composition in Parkinson's disease. Mov. Disord. 30 (10), 1351–1360. doi:10.1002/mds.26307

PubMed Abstract | CrossRef Full Text | Google Scholar

Killinger, B. A., Melki, R., Brundin, P., and Kordower, J. H. (2019). Endogenous alpha-synuclein monomers, oligomers and resulting pathology: let’s talk about the lipids in the room. Npj Parkinson’s Dis. 5 (1), 23–40. doi:10.1038/s41531-019-0095-3

PubMed Abstract | CrossRef Full Text | Google Scholar

Kim, S., Kwon, S. H., Kam, T. I., Panicker, N., Karuppagounder, S. S., Lee, S., et al. (2019). Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson's disease. Neuron 103 (4), 627–641. doi:10.1016/j.neuron.2019.05.035

PubMed Abstract | CrossRef Full Text | Google Scholar

Kitani-Morii, F., Friedland, R. P., Yoshida, H., and Mizuno, T. (2021). Drosophila as a model for microbiota studies of neurodegeneration. J. Alzheimer’s Dis. 84 (2), 479–490. doi:10.3233/JAD-215031

CrossRef Full Text | Google Scholar

Komleva, Y., Chernykh, A., Lopatina, O., Gorina, Y., Lokteva, I., Salmina, A., et al. (2021). Inflamm-aging and brain insulin resistance: New insights and role of life-style strategies on cognitive and social determinants in aging and neurodegeneration. Front. Neurosci. 1, 618395. –17. doi:10.3389/fnins.2020.618395

CrossRef Full Text | Google Scholar

Kong, Y., Jiang, B., and Luo, X. (2018). Gut microbiota influences Alzheimer's disease pathogenesis by regulating acetate in Drosophila model. Future Microbiol. 13, 1117–1128. doi:10.2217/fmb-2018-0185

PubMed Abstract | CrossRef Full Text | Google Scholar

Kou, J., Kovacs, G. G., Höftberger, R., Kulik, W., Brodde, A., Forss-Petter, S., et al. (2011). Peroxisomal alterations in Alzheimer’s disease. Acta Neuropathol. 122 (3), 271–283. doi:10.1007/s00401-011-0836-9

PubMed Abstract | CrossRef Full Text | Google Scholar

Kounatidis, I., Chtarbanova, S., Cao, Y., Hayne, M., Jayanth, D., Ganetzky, B., et al. (2017). NF-κB immunity in the brain determines fly lifespan in healthy aging and age-related neurodegeneration. Cell Rep. 19 (4), 836–848. doi:10.1016/j.celrep.2017.04.007

PubMed Abstract | CrossRef Full Text | Google Scholar

Kovacs, G. G., Kwong, L. K., Grossman, M., Irwin, D. J., Lee, E. B., Robinson, J. L., et al. (2018). Tauopathy with hippocampal 4-repeat tau immunoreactive spherical inclusions: A report of three cases. Brain pathol. 28 (2), 274–283. doi:10.1111/bpa.12482

PubMed Abstract | CrossRef Full Text | Google Scholar

Kowalski, K., and Mulak, A. (2019). Brain-gut-microbiota Axis in alzheimer's disease. Neurogastroenterol. Motil. 25 (1), 48–60. doi:10.5056/jnm18087

CrossRef Full Text | Google Scholar

Kretzschmar, D., Hasan, G., Sharma, S., Heisenberg, M., and Benzer, S. (1997). The Swiss cheese mutant causes glial hyperwrapping and brain degeneration in Drosophila.

Google Scholar

Kubrak, K., Koyama, T., Ahrentløv, N., Jensen, L., Malita, A., Naseem, M. T., et al. (2022). The gut hormone Allatostatin C/Somatostatin regulates food intake and metabolic homeostasis under nutrient stress. Natur. Commun. 13 (1), 692. doi:10.1038/s41467-022-28268-x

CrossRef Full Text | Google Scholar

Lam, Y. Y., Ha, C. W., Hoffmann, J. M., Oscarsson, J., Dinudom, A., Mather, T. J., et al. (2015). Effects of dietary fat profile on gut permeability and microbiota and their relationships with metabolic changes in mice. Obesity 23 (7), 1429–1439. doi:10.1002/oby.21122

PubMed Abstract | CrossRef Full Text | Google Scholar

Lancaster, G. I., Langley, K. G., Berglund, N. A., Kammoun, H. L., Reibe, S., Estevez, E., et al. (2018). Evidence that TLR4 is not a receptor for saturated fatty acids but mediates lipid-induced inflammation by reprogramming macrophage metabolism. Cell metabol. 27 (5), 1096–1110. doi:10.1016/j.cmet.2018.03.014

PubMed Abstract | CrossRef Full Text | Google Scholar

Lankelma, J. M., Nieuwdorp, M., de Vos, W. M., and Wiersinga, W. J. (2015). The gut microbiota in internal medicine: Implications for health and disease. Neth. J. Med. 73 (2), 61–68.

PubMed Abstract | Google Scholar

Lee, V. M., Goedert, M., and Trojanowski, J. Q. (2001). Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121–1159. doi:10.1146/annurev.neuro.24.1.1121

PubMed Abstract | CrossRef Full Text | Google Scholar

Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., et al. (2012). Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 18 (2), 291–295. doi:10.1038/nm.2613

PubMed Abstract | CrossRef Full Text | Google Scholar

Levenson, R. W., Sturm, V. E., and Haase, C. M. (2014). Emotional and behavioral symptoms in neurodegenerative disease: A model for studying the neural bases of psychopathology. Annu. Rev. Clin. Psychol. 10, 581–606. doi:10.1146/annurev-clinpsy-032813-153653

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, C. Q., Zheng, Q., Wang, Q., and Zeng, Q. P. (2016). Biotic/abiotic stress-driven alzheimer's disease. Front. Cell Neurosci. 10, 269. doi:10.3389/fncel.2016.00269

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, H., Li, S., Yang, H., Zhang, Y., Zhang, S., Ma, Y., et al. (2022). Association of ultraprocessed food consumption with risk of dementia: A prospective cohort study. Neurology 99, e1056–e1066. doi:10.1212/WNL.0000000000200871

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, N. M., Liu, K. F., Qiu, Y. J., Zhang, H. H., Nakanishi, H., and Qing, H. (2019). Mutations of beta-amyloid precursor protein alter the consequence of Alzheimer’s disease pathogenesis. Neural Regen. Res. 14 (4), 658–665. doi:10.4103/1673-5374.247469

PubMed Abstract | CrossRef Full Text | Google Scholar

Lithfous, S., Dufour, A., and Després, O. (2013). Spatial navigation in normal aging and the prodromal stage of alzheimer's disease: Insights from imaging and behavioral studies. Ageing Res. Rev. 12 (1), 201–213. doi:10.1016/j.arr.2012.04.007

PubMed Abstract | CrossRef Full Text | Google Scholar

Liu, S. (2018). Neurotrophic factors in enteric physiology and pathophysiology. Neurogastroenterol. Motil. 30 (10), e13446. doi:10.1111/nmo.13446

PubMed Abstract | CrossRef Full Text | Google Scholar

Liu, Y., Wei, W., Baazaoui, N., Liu, F., and Iqbal, K. (2019). Inhibition of AMD-like pathology with a neurotrophic compound in aged rats and 3xTg-AD mice. Front. aging Neurosci. 11, 309. doi:10.3389/fnagi.2019.00309

PubMed Abstract | CrossRef Full Text | Google Scholar

López-Armada, M. J., Riveiro-Naveira, R. R., Vaamonde-García, C., and Valcárcel-Ares, M. N. (2013). Mitochondrial dysfunction and the inflammatory response. Mitochondrion 13 (2), 106–118. doi:10.1016/j.mito.2013.01.003

PubMed Abstract | CrossRef Full Text | Google Scholar

Lu, B., and Vogel, H. (2009). Drosophila models of neurodegenerative diseases. Annu. Rev. Pathol. 4, 315–342. doi:10.1146/annurev.pathol.3.121806.151529

PubMed Abstract | CrossRef Full Text | Google Scholar

Lundmark, K., Westermark, G. T., Olsén, A., and Westermark, P. (2005). Protein fibrils in nature can enhance amyloid protein A amyloidosis in mice: Cross-seeding as a disease mechanism. Proc. Natl. Acad. Sci. U. S. A. 102 (17), 6098–6102. doi:10.1073/pnas.0501814102

PubMed Abstract | CrossRef Full Text | Google Scholar

Lye, S. H., and Chtarbanova, S. (2018). Drosophila as a model to study brain innate immunity in health and disease. Int. J. Mol. Sci. 19 (12), 3922. doi:10.3390/ijms19123922

PubMed Abstract | CrossRef Full Text | Google Scholar

Lyte, M. (2013). Microbial endocrinology in the microbiome-gut-brain axis: How bacterial production and utilization of neurochemicals influence behavior. PLoS Pathog. 9 (11), e1003726. doi:10.1371/journal.ppat.1003726

PubMed Abstract | CrossRef Full Text | Google Scholar

Lyte, M. (2014). Microbial endocrinology: Host-microbiota neuroendocrine interactions influencing brain and behavior. Gut microbes 5 (3), 381–389. doi:10.4161/gmic.28682

PubMed Abstract | CrossRef Full Text | Google Scholar

Ma, Q., Xing, C., Long, W., Wang, H. Y., Liu, Q., and Wang, R. F. (2019). Impact of microbiota on central nervous system and neurological diseases: The gut-brain axis. J. neuroinflamm 16 (1), 53. doi:10.1186/s12974-019-1434-3

PubMed Abstract | CrossRef Full Text | Google Scholar

Marizzoni, M., Provasi, S., Cattaneo, A., and Frisoni, G. B. (2017). Microbiota and neurodegenerative diseases. Curr. Opin. Neurol. 30 (6), 630–638. doi:10.1097/WCO.0000000000000496

PubMed Abstract | CrossRef Full Text | Google Scholar

Marra, A., Hanson, M. A., Kondo, S., Erkosar, B., and Lemaitre, B. (2021). Drosophila antimicrobial peptides and lysozymes regulate gut microbiota composition and abundance. mBio 12 (4), e0082421. doi:10.1128/mBio.00824-21

PubMed Abstract | CrossRef Full Text | Google Scholar

Martin, C. A., and Krantz, D. E. (2014). Drosophila melanogaster as a genetic model system to study neurotransmitter transporters. Neurochem. Int. 73, 71–88. doi:10.1016/j.neuint.2014.03.015

PubMed Abstract | CrossRef Full Text | Google Scholar

Martin-Morris, L. E., and White, K. (1990). The Drosophila transcript encoded by the beta-amyloid protein precursor-like gene is restricted to the nervous system. Development 110 (1), 185–195. doi:10.1242/dev.110.1.185

PubMed Abstract | CrossRef Full Text | Google Scholar

Mayfeild (2010). MayfeildClinic.com. Parkinson’s Dis. 27 (1), 1–5.

Google Scholar

McHugh, D., and Gil, J. (2018). Senescence and aging: Causes, consequences, and therapeutic avenues. J. Cell Biol. 217 (1), 65–77. doi:10.1083/jcb.201708092

PubMed Abstract | CrossRef Full Text | Google Scholar

Mertsalmi, T. H., Pekkonen, E., and Scheperjans, F. (2020). Antibiotic exposure and risk of Parkinson’s disease in Finland: A nationwide case-control study. Mov. Disord. 35 (3), 431–442. doi:10.1002/mds.27924

PubMed Abstract | CrossRef Full Text | Google Scholar

Mesulam, M., Shaw, P., Mash, D., and Weintraub, S. (2004). Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann. neurol 55 (6), 815–828. doi:10.1002/ana.20100

PubMed Abstract | CrossRef Full Text | Google Scholar

Mielke, M. M. (2018). Sex and gender differences in alzheimer's disease dementia. Psychiatr. Times 35 (11), 14–17. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390276/.

PubMed Abstract | Google Scholar

Minter, M. R., Zhang, C., Leone, V., Ringus, D. L., Zhang, X., Oyler-Castrillo, P., et al. (2016). Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. Sci. Rep. 6, 30028. doi:10.1038/srep30028

PubMed Abstract | CrossRef Full Text | Google Scholar

Mohandas, E., Rajmohan, V., and Raghunath, B. (2009). Neurobiology of Alzheimer's disease. Indian J. Psychiatry 51 (1), 55–61. doi:10.4103/0019-5545.44908

PubMed Abstract | CrossRef Full Text | Google Scholar

Moisan, F., Kab, S., Mohamed, F., Canonico, M., Le Guern, M., Quintin, C., et al. (2016). Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. Neurol. Neurosurg. Psychiatry 87 (9), 952–957. doi:10.1136/jnnp-2015-312283

PubMed Abstract | CrossRef Full Text | Google Scholar

Monaco, G., van Dam, S., Casal Novo Ribeiro, J. L., Larbi, A., and de Magalhães, J. P. (2015). A comparison of human and mouse gene co-expression networks reveals conservation and divergence at the tissue, pathway and disease levels. BMC Evol. Bio 15, 259. doi:10.1186/s12862-015-0534-7

PubMed Abstract | CrossRef Full Text | Google Scholar

Morley, J. E., Farr, S. A., and Nguyen, A. D. (2018). Alzheimer disease. Clin. Geriatr. Med. 34 (4), 591–601. doi:10.1016/j.cger.2018.06.006

PubMed Abstract | CrossRef Full Text | Google Scholar

Morowitz, M. J., Carlisle, E. M., and Alverdy, J. C. (2011). Contributions of intestinal bacteria to nutrition and metabolism in the critically ill. Surg. Clin. North Am. 91 (4), 771–785. doi:10.1016/j.suc.2011.05.001

PubMed Abstract | CrossRef Full Text | Google Scholar

Muddapu, V. R., Dharshini, S. A. P., Chakravarthy, V. S., and Gromiha, M. M. (2020). Neurodegenerative diseases – is metabolic deficiency the root cause? Front. Neurosci. 14, 213–219. doi:10.3389/fnins.2020.00213

PubMed Abstract | CrossRef Full Text | Google Scholar

Murphy, M. P., and LeVine, H. (2010). Alzheimer's disease and the amyloid-beta peptide. J. Alzheimer's Dis. 19 (1), 311–323. doi:10.3233/JAD-2010-1221

CrossRef Full Text | Google Scholar

Muzio, L., Viotti, A., and Martino, G. (2021). Microglia in neuroinflammation and neurodegeneration: From understanding to therapy. Front. Neurosci. 15, 742065. doi:10.3389/fnins.2021.742065

PubMed Abstract | CrossRef Full Text | Google Scholar

Myllymäki, H., Valanne, S., and Rämet, M. (2014). The Drosophila imd signaling pathway. J. Immunol. 192 (8), 3455–3462. doi:10.4049/jimmunol.1303309

PubMed Abstract | CrossRef Full Text | Google Scholar

Nadkarni, N. K., Mawji, E., McIlroy, W. E., and Black, S. E. (2009). Spatial and temporal gait parameters in Alzheimer's disease and aging. Gait Post. 30 (4), 452–454. doi:10.1016/j.gaitpost.2009.07.003

PubMed Abstract | CrossRef Full Text | Google Scholar

Nam, E., Derrick, J. S., Lee, S., Kang, J., Han, J., Lee, S., et al. (2018). Regulatory activities of dopamine and its derivatives toward metal-free and metal-induced amyloid-β aggregation, oxidative stress, and inflammation in alzheimer's disease. ACS Chem. Neurosci. 9 (11), 2655–2666. doi:10.1021/acschemneuro.8b00122

PubMed Abstract | CrossRef Full Text | Google Scholar

Neary, D., Snowden, J. S., Mann, D. M., Northern, B., Goulding, P. J., and Macdermott, N. (1990). Frontal lobe dementia and motor neuron disease. J. Neurol. Neurosurg. Psychiatry 53 (1), 23–32. doi:10.1136/jnnp.53.1.23

PubMed Abstract | CrossRef Full Text | Google Scholar

Neophytou, C., and Pitsouli, C. (2022). How gut microbes nurture intestinal stem cells: A Drosophila perspective. Metabolites 12 (2), 169. doi:10.3390/metabo12020169

PubMed Abstract | CrossRef Full Text | Google Scholar

Newell, P. D., and Douglas, A. E. (2014). Interspecies interactions determine the impact of the gut microbiota on nutrient allocation in Drosophila melanogaster. Appl. Environ. Microbiol. 80 (2), 788–796. doi:10.1128/AEM.02742-13

PubMed Abstract | CrossRef Full Text | Google Scholar

Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., et al. (2001). Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 (8), 759–767. doi:10.1093/jnen/60.8.759

PubMed Abstract | CrossRef Full Text | Google Scholar

O'Brien, R. J., and Wong, P. C. (2011). Amyloid precursor protein processing and Alzheimer's disease. Annu. Rev. Neurosci. 34, 185–204. doi:10.1146/annurev-neuro-061010-113613

PubMed Abstract | CrossRef Full Text | Google Scholar

O'Mahony, S. M., Clarke, G., Borre, Y. E., Dinan, T. G., and Cryan, J. F. (2015). Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav. Brain Res. 277, 32–48. doi:10.1016/j.bbr.2014.07.027

PubMed Abstract | CrossRef Full Text | Google Scholar

Okamoto, N., and Watanabe, A. (2022). Interorgan communication through peripherally derived peptide hormones in Drosophila. Fly 16 (1), 152–176. doi:10.1080/19336934.2022.2061834

PubMed Abstract | CrossRef Full Text | Google Scholar

Onyango, I. G., Jauregui, G. V., Carná, M.,J. P. B., and Stokin, G. B. (2015). Neuroinflamm alzheimer’s disease, 243–256.

Google Scholar

Ordonez, D. G., Lee, M. K., and Feany, M. B. (2018). α-Synuclein induces mitochondrial dysfunction through spectrin and the actin cytoskeleton. Neuron 97 (1), 108–124. doi:10.1016/j.neuron.2017.11.036

PubMed Abstract | CrossRef Full Text | Google Scholar

Osellame, L. D., Blacker, T. S., and Duchen, M. R. (2012). Cellular and molecular mechanisms of mitochondrial function. Clin endocrinol metabol 26 (6), 711–723. doi:10.1016/j.beem.2012.05.003

PubMed Abstract | CrossRef Full Text | Google Scholar

Ou, Z., Pan, J., Tang, S., Duan, D., Yu, D., Nong, H., et al. (2021). Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019. Front. Public Health 9, 776847. doi:10.3389/fpubh.2021.776847

PubMed Abstract | CrossRef Full Text | Google Scholar

Pang, S. Y., Teo, K. C., Hsu, J. S., Chang, R. S., Li, M., Sham, P. C., et al. (2017). The role of gene variants in the pathogenesis of neurodegenerative disorders as revealed by next generation sequencing studies: A review. Transl. Neurodegener. 6, 27. doi:10.1186/s40035-017-0098-0

PubMed Abstract | CrossRef Full Text | Google Scholar

Pardridge, W. M. (2012). Drug transport across the blood-brain barrier. J. Cereb. Blood Flow. Metab. 32 (11), 1959–1972. doi:10.1038/jcbfm.2012.126

PubMed Abstract | CrossRef Full Text | Google Scholar

Paul, B., Barnes, S., Demark-Wahnefried, W., Morrow, C., Salvador, C., Skibola, C., et al. (2015). Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases. Clin. epigenet 7, 112. doi:10.1186/s13148-015-0144-7

PubMed Abstract | CrossRef Full Text | Google Scholar

Perrimon, N., Bonini, N. M., and Dhillon, P. (2016). Fruit flies on the front line: The translational impact of Drosophila. Dis. Model Mech. 9 (3), 229–231. doi:10.1242/dmm.024810

PubMed Abstract | CrossRef Full Text | Google Scholar

Peters, R. (2006). Ageing and the brain. Postgrad. Med. J. 82 (964), 84–88. doi:10.1136/pgmj.2005.036665

PubMed Abstract | CrossRef Full Text | Google Scholar

Peterson, C. T. (2020). Dysfunction of the microbiota-gut-brain Axis in neurodegenerative disease: The promise of therapeutic modulation with prebiotics, medicinal herbs, probiotics, and synbiotics. J. evidence-based Integr. Med. 25, 2515690X20957225. doi:10.1177/2515690X20957225

PubMed Abstract | CrossRef Full Text | Google Scholar

Peterson, L. W., and Artis, D. (2014). Intestinal epithelial cells: Regulators of barrier function and immune homeostasis. Immunology 14 (3), 141–153. doi:10.1038/nri3608

PubMed Abstract | CrossRef Full Text | Google Scholar

Pini, L., Pievani, M., Bocchetta, M., Altomare, D., Bosco, P., Cavedo, E., et al. (2016). Brain atrophy in Alzheimer's Disease and aging. Ageing Res. Rev. 30, 25–48. doi:10.1016/j.arr.2016.01.002

PubMed Abstract | CrossRef Full Text | Google Scholar

Pisani, V., Stefani, A., Pierantozzi, M., Natoli, S., Stanzione, P., Franciotta, D., et al. (2012). Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease. J. neuroinflammation 9, 188. doi:10.1186/1742-2094-9-188

PubMed Abstract | CrossRef Full Text | Google Scholar

Podcasy, J. L., and Epperson, C. N. (2016). Considering sex and gender in Alzheimer disease and other dementias. Dialogues Clin. Neurosci. 18 (4), 437–446. doi:10.31887/DCNS.2016.18.4/cepperson

PubMed Abstract | CrossRef Full Text | Google Scholar

Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., et al. (2017). Parkinson disease. Nat. Rev. 3, 17013. doi:10.1038/nrdp.2017.13

PubMed Abstract | CrossRef Full Text | Google Scholar

Pottorf, T. S., Nocera, J. R., Eicholtz, S. P., and Kesar, T. M. (2022). Locomotor adaptation deficits in older individuals with cognitive impairments: A pilot study. Front. Neurol. 13, 800338. doi:10.3389/fneur.2022.800338

PubMed Abstract | CrossRef Full Text | Google Scholar

Prüßing, K., Voigt, A., and Schulz, J. B. (2013). Drosophila melanogaster as a model organism for Alzheimer’s disease. Mol. Neurodegener. 8 (1), 35. doi:10.1186/1750-1326-8-35

PubMed Abstract | CrossRef Full Text | Google Scholar

Pulikkan, J., Mazumder, A., and Grace, T. (2019). Role of the gut microbiome in autism spectrum disorders. Adv. Exp. Med. Biol. 1118, 253–269. doi:10.1007/978-3-030-05542-4_13

PubMed Abstract | CrossRef Full Text | Google Scholar

Qi, Y., Lohman, J., Bratlie, K. M., Peroutka-Bigus, N., Bellaire, B., Wannemuehler, M., et al. (2019). Vitamin C and B3 as new biomaterials to alter intestinal stem cells. J. Biomed. Mat. Res. 107 (9), 1886–1897. doi:10.1002/jbm.a.36715

PubMed Abstract | CrossRef Full Text | Google Scholar

Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, , et al. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464 (7285), 59–65. doi:10.1038/nature08821

PubMed Abstract | CrossRef Full Text | Google Scholar

Raff, M. C., Whitmore, A. V., and Finn, J. T. (2002). Axonal self-destruction and neurodegeneration. Science 296 (5569), 868–871. doi:10.1126/science.1068613

PubMed Abstract | CrossRef Full Text | Google Scholar

Raskin, J., Cummings, J., Hardy, J., Schuh, K., and Dean, R. (2015). Neurobiology of alzheimer’s disease: Integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions. Curr. Alzheimer Res. 12 (8), 712–722. doi:10.2174/1567205012666150701103107

PubMed Abstract | CrossRef Full Text | Google Scholar

Ratnayaka, J. A., Serpell, L. C., and Lotery, A. J. (2015). Dementia of the eye: The role of amyloid beta in retinal degeneration. Eye 29 (8), 1013–1026. doi:10.1038/eye.2015.100

PubMed Abstract | CrossRef Full Text | Google Scholar

Raz, E. (2010). Mucosal immunity: Aliment and ailments. Mucos Immunol. 3 (1), 4–7. doi:10.1038/mi.2009.123

PubMed Abstract | CrossRef Full Text | Google Scholar

Reddy, P. H., and Beal, M. F. (2008). Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and alzheimer's disease. Trends Mol. Med. 14 (2), 45–53. doi:10.1016/j.molmed.2007.12.002

PubMed Abstract | CrossRef Full Text | Google Scholar

Reddy, P. H. (2009). Role of mitochondria in neurodegenerative diseases: Mitochondria as a therapeutic target in alzheimer's disease. CNS Spectr. 14 (7), 8–13. doi:10.1017/s1092852900024901

PubMed Abstract | CrossRef Full Text | Google Scholar

Rhea, E. M., and Banks, W. A. (2021). Interactions of lipids, lipoproteins, and apolipoproteins with the blood-brain barrier. Pharma Res. 38 (9), 1469–1475. doi:10.1007/s11095-021-03098-6

CrossRef Full Text | Google Scholar

Richards, P., Thornberry, N. A., and Pinto, S. (2021). The gut-brain axis: Identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders. Mol. Metabol. 46, 101175. doi:10.1016/j.molmet.2021.101175

CrossRef Full Text | Google Scholar

Rinninella, E., Raoul, P., Cintoni, M., Franceschi, F., Miggiano, G. A. D., Gasbarrini, A., et al. (2019). What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms 7 (1), 14. doi:10.3390/microorganisms7010014

PubMed Abstract | CrossRef Full Text | Google Scholar

Roczkowsky, A., Doan, M. A. L., Hlavay, B., Mamik, M. K., Branton, W. G., McKenzie, B. A., et al. (2022). Peroxisome injury in multiple sclerosis: Protective effects of 4-phenylbutyrate in CNS-associated macrophages. J. Neurosci. 42 (37), 7152–7165. doi:10.1523/JNEUROSCI.0312-22.2022

PubMed Abstract | CrossRef Full Text | Google Scholar

Roostaei, T., Nazeri, A., Felsky, D., De Jager, P. L., Schneider, J. A., Pollock, B. G., et al. (2017). Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease. Molec psychiatry 22 (2), 287–295. doi:10.1038/mp.2016.35

PubMed Abstract | CrossRef Full Text | Google Scholar

Rosen, D. R., Martin-Morris, L., Luo, L. Q., and White, K. (1989). A Drosophila gene encoding a protein resembling the human beta-amyloid protein precursor. Proc. Natl. Acad. Sci. U. S. A. 86 (7), 2478–2482. doi:10.1073/pnas.86.7.2478

PubMed Abstract | CrossRef Full Text | Google Scholar

Rydbom, J., Kohl, H., Hyde, V. R., and Lohr, K. M. (2021). Altered gut microbial load and immune activation in a Drosophila model of human tauopathy. Front. Neurosci. 15 (731602), 731602–731609. doi:10.3389/fnins.2021.731602

PubMed Abstract | CrossRef Full Text | Google Scholar

Saeedi, M., and Rashidy-Pour, A. (2021). Association between chronic stress and Alzheimer's disease: Therapeutic effects of Saffron. Biomed. Pharmacother. = Biomedecine Pharmacother. 133, 110995. doi:10.1016/j.biopha.2020.110995

PubMed Abstract | CrossRef Full Text | Google Scholar

Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., et al. (2016). Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 167 (6), 1469–1480. doi:10.1016/j.cell.2016.11.018

PubMed Abstract | CrossRef Full Text | Google Scholar

Sampson, T. R., and Sarkis, M. K. (2015). Control of brain development, function, and behavior by the microbiome. Cell host microbe 17 (5), 565–576. doi:10.1016/j.chom.2015.04.011

PubMed Abstract | CrossRef Full Text | Google Scholar

Sánchez-Ferro, Á., Rábano, A., Catalán, M. J., Rodríguez-Valcárcel, F. C., Fernández Díez, S., Herreros-Rodríguez, J., et al. (2015). In vivo gastric detection of α-synuclein inclusions in Parkinson's disease. Mov. Disord. 30 (4), 517–524. doi:10.1002/mds.25988

PubMed Abstract | CrossRef Full Text | Google Scholar

Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., et al. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 (5733), 476–481. doi:10.1126/science.1113694

PubMed Abstract | CrossRef Full Text | Google Scholar

Sarantseva, S., Timoshenko, S., Bolshakova, O., Karaseva, E., Rodin, D., Schwarzman, A. L., et al. (2009). Apolipoprotein E-mimetics inhibit neurodegeneration and restore cognitive functions in a transgenic Drosophila model of Alzheimer’s disease. PLoS ONE 4 (12), e8191. doi:10.1371/journal.pone.0008191

PubMed Abstract | CrossRef Full Text | Google Scholar

Scaioli, E., Liverani, E., and Belluzzi, A. (2017). The imbalance between n-6/n-3 polyunsaturated fatty acids and inflammatory bowel disease: A comprehensive review and future therapeutic perspectives. Int. J. molec Sci. 18 (12), 2619. doi:10.3390/ijms18122619

CrossRef Full Text | Google Scholar

Schäfer, A., Chaggar, P., Thompson, T. B., Goriely, A., and Kuhl, E. (2021). Predicting brain atrophy from tau pathology: A summary of clinical findings and their translation into personalized models. Brain Multiphys 2, 100039. doi:10.1016/j.brain.2021.100039

CrossRef Full Text | Google Scholar

Scheperjans, F., Aho, V., Pereira, P. A., Koskinen, K., Paulin, L., Pekkonen, E., et al. (2015). Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov. Disord. 30 (3), 350–358. doi:10.1002/mds.26069

PubMed Abstract | CrossRef Full Text | Google Scholar

Schoeler, M., and Caesar, R. (2019). Dietary lipids, gut microbiota and lipid metabolism. Curr. Opin. Endocr. Metab. Disord. 20 (4), 461–472. doi:10.1007/s11154-019-09512-0

PubMed Abstract | CrossRef Full Text | Google Scholar

Schretter, C. E. (2020). Links between the gut microbiota, metabolism, and host behavior. Gut Microbe 11 (2), 245–248. doi:10.1080/19490976.2019.1643674

PubMed Abstract | CrossRef Full Text | Google Scholar

Schretter, C. E., Vielmetter, J., Bartos, I., Marka, Z., Marka, S., Argade, S., et al. (2018). A gut microbial factor modulates locomotor behaviour in Drosophila. Nature 563 (7731), 402–406. doi:10.1038/s41586-018-0634-9

PubMed Abstract | CrossRef Full Text | Google Scholar

Semar, S., Klotz, M., Letiembre, M., Van Ginneken, C., Braun, A., Jost, V., et al. (2013). Changes of the enteric nervous system in amyloid-β protein precursor transgenic mice correlate with disease progression. J. Alzheimer's Dis. 36 (1), 7–20. doi:10.3233/JAD-120511

PubMed Abstract | CrossRef Full Text | Google Scholar

Sender, R., Fuchs, S., and Milo, R. (2016). Revised estimates for the number of human and bacteria cells in the body. PloS Bio 14 (8), e1002533. doi:10.1371/journal.pbio.1002533

PubMed Abstract | CrossRef Full Text | Google Scholar

Shadfar, S., Hwang, C. J., Lim, M. S., Choi, D. Y., and Hong, J. T. (2015). Involvement of inflammation in Alzheimer’s disease pathogenesis and therapeutic potential of anti-inflammatory agents. Arch. Pharm. Res. 38 (12), 2106–2119. doi:10.1007/s12272-015-0648-x

PubMed Abstract | CrossRef Full Text | Google Scholar

Shahmoradian, S. H., Lewis, A. J., Genoud, C., Hench, J., Moors, T. E., Navarro, P. P., et al. (2019). Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 22 (7), 1099–1109. doi:10.1038/s41593-019-0423-2

PubMed Abstract | CrossRef Full Text | Google Scholar

Shannon, K. M., Keshavarzian, A., Dodiya, H. B., Jakate, S., and Kordower, J. H. (2012). Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov. Disord. 27 (6), 716–719. doi:10.1002/mds.25020

PubMed Abstract | CrossRef Full Text | Google Scholar

Shibata, M., Hisajima, T., Nakano, M., Goris, R. C., and Funakoshi, K. (2008). Morphological relationships between peptidergic nerve fibers and immunoglobulin A-producing lymphocytes in the mouse intestine. Brain, Behav. Immun. 22 (2), 158–166. doi:10.1016/j.bbi.2007.08.013

PubMed Abstract | CrossRef Full Text | Google Scholar

Silva, Y. P., Bernardi, A., and Frozza, R. L. (2020). The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front. Endocrinol. 11, 25. doi:10.3389/fendo.2020.00025

CrossRef Full Text | Google Scholar

Simon, M. (2018). The amyloid hypothesis on trial. Nature 559, S4–S7. doi:10.1038/d41586-018-05719-4

PubMed Abstract | CrossRef Full Text | Google Scholar

Smith, J. J., and Aitchison, J. D. (2013). Peroxisomes take shape. Nat. Rev. Mol. Cell Biol. 14 (12), 803–817. doi:10.1038/nrm3700

PubMed Abstract | CrossRef Full Text | Google Scholar

Sochocka, M., Donskow-Łysoniewska, K., Diniz, B. S., Kurpas, D., Brzozowska, E., and Leszek, J. (2019). The gut microbiome alterations and inflammation-driven pathogenesis of alzheimer's disease-a critical review. Molec Neurobiol. 56 (3), 1841–1851. doi:10.1007/s12035-018-1188-4

CrossRef Full Text | Google Scholar

Song, W., Veenstra, J. A., and Perrimon, N. (2014). Control of lipid metabolism by tachykinin in Drosophila. Cell Rep. 9 (1), 40–47. doi:10.1016/j.celrep.2014.08.060

PubMed Abstract | CrossRef Full Text | Google Scholar

Sonne, J., Reddy, V., and Beato, M. R. (2021). “Neuroanatomy, substantia nigra,” in StatPearls. Available at: https://www.ncbi.nlm.nih.gov/books/NBK536995/.

Google Scholar

Spillantini, M. G., and Goedert, M. (2013). Tau pathology and neurodegeneration. Lancet. Neurol. 12 (6), 609–622. doi:10.1016/S1474-4422(13)70090-5

PubMed Abstract | CrossRef Full Text | Google Scholar

Spinelli, M., Fusco, S., and Grassi, C. (2019). Brain insulin resistance and hippocampal plasticity: Mechanisms and biomarkers of cognitive decline. Front. Neurosci. 13 (788), 788. doi:10.3389/fnins.2019.00788

PubMed Abstract | CrossRef Full Text | Google Scholar

St Laurent, R., O'Brien, L. M., and Ahmad, S. T. (2013). Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease. Neuroscience 246, 382–390. doi:10.1016/j.neuroscience.2013.04.037

PubMed Abstract | CrossRef Full Text | Google Scholar

Staff, N. P., and Windebank, A. J. (2014). Peripheral neuropathy due to vitamin deficiency, toxins, and medications. Continuum 20, 1293–1306. doi:10.1212/01.CON.0000455880.06675.5a

PubMed Abstract | CrossRef Full Text | Google Scholar

Stanford, A. H., Gong, H., Noonan, M., Lewis, A. N., Gong, Q., Lanik, W. E., et al. (2020). A direct comparison of mouse and human intestinal development using epithelial gene expression patterns. Pediatr. Res. 88 (1), 66–76. doi:10.1038/s41390-019-0472-y

PubMed Abstract | CrossRef Full Text | Google Scholar

Stavrinou, P. S., Andreou, E., Aphamis, G., Pantzaris, M., Ioannou, M., Patrikios, I. S., et al. (2020). The effects of a 6-month high dose omega-3 and omega-6 polyunsaturated fatty acids and antioxidant vitamins supplementation on cognitive function and functional capacity in older adults with mild cognitive impairment. Nutrients 12 (2), 325. doi:10.3390/nu12020325

PubMed Abstract | CrossRef Full Text | Google Scholar

Steinkamp, M., Schulte, N., Spaniol, U., Pflüger, C., Hartmann, C., Kirsch, J., et al. (2012). Brain derived neurotrophic factor inhibits apoptosis in enteric glia during gut inflammation. Med. Sci. Monit. 18 (4), 117–122. doi:10.12659/msm.882612

PubMed Abstract | CrossRef Full Text | Google Scholar

Stilling, R. M., Dinan, T. G., and Cryan, J. F. (2014). Microbial genes, brain and behaviour - epigenetic regulation of the gut-brain axis. Genes, Brain, Behav. 13 (1), 69–86. doi:10.1111/gbb.12109

PubMed Abstract | CrossRef Full Text | Google Scholar

Stilling, R. M., van de Wouw, M., Clarke, G., Stanton, C., Dinan, T. G., and Cryan, J. F. (2016). The neuropharmacology of butyrate: The bread and butter of the microbiota-gut-brain axis? Neurochem. Int. 99, 110–132. doi:10.1016/j.neuint.2016.06.011

PubMed Abstract | CrossRef Full Text | Google Scholar

Stokholm, M. G., Danielsen, E. H., Hamilton-Dutoit, S. J., and Borghammer, P. (2016). Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann. Neurol. 79 (6), 940–949. doi:10.1002/ana.24648

PubMed Abstract | CrossRef Full Text | Google Scholar

Storelli, G., Defaye, A., Erkosar, B., Hols, P., Royet, J., and Leulier, F. (2011). Lactobacillus plantarum promotes Drosophila systemic growth by modulating hormonal signals through TOR-dependent nutrient sensing. Cell Metab. 14, 403–414. doi:10.1016/j.cmet.2011.07.012

PubMed Abstract | CrossRef Full Text | Google Scholar

Strand, B. H., Knapskog, A. B., Persson, K., Edwin, T. H., Amland, R., Mjørud, M., et al. (2018). Survival and years of life lost in various aetiologies of dementia, mild cognitive impairment (MCI) and subjective cognitive decline (SCD) in Norway. PloS one 13 (9), e0204436. doi:10.1371/journal.pone.0204436

PubMed Abstract | CrossRef Full Text | Google Scholar

Sun, Y., Sommerville, N. R., Liu, J., Ngan, M. P., Poon, D., Ponomarev, E. D., et al. (2020). Intra-gastrointestinal amyloid-β1-42 oligomers perturb enteric function and induce Alzheimer's disease pathology. J. Physiol. 598 (19), 4209–4223. doi:10.1113/JP279919

PubMed Abstract | CrossRef Full Text | Google Scholar

Svenningsson, A. L., Stomrud, E., Insel, P. S., Mattsson, N., Palmqvist, S., and Hansson, O. (2019). β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. Sci. Rep. 9 (1), 11180. doi:10.1038/s41598-019-47638-y

PubMed Abstract | CrossRef Full Text | Google Scholar

Swanson, D., Block, R., and Mousa, S. A. (2012). Omega-3 fatty acids EPA and DHA: Health benefits throughout life. Adv. Nutr. 3 (1), 1–7. doi:10.3945/an.111.000893

PubMed Abstract | CrossRef Full Text | Google Scholar

Takasugi, N., Tomita, T., Hayashi, I., Tsuruoka, M., Niimura, M., Takahashi, Y., et al. (2003). The role of presenilin cofactors in the gamma-secretase complex. Nature 422 (6930), 438–441. doi:10.1038/nature01506

PubMed Abstract | CrossRef Full Text | Google Scholar

Takeda, K., Okumura, T., Terahata, M., Yamaguchi, M., Taniguchi, K., and Adachi-Yamada, T. (2018). Drosophila peptide hormones allatostatin A and diuretic hormone 31 exhibiting complementary gradient distribution in posterior midgut antagonistically regulate midgut senescence and adult lifespan. Zool. Sci. 35 (1), 75–85. doi:10.2108/zs160210

CrossRef Full Text | Google Scholar

Tamagno, E., Guglielmotto, M., Vasciaveo, V., and Tabaton, M. (2021). Oxidative stress and beta amyloid in alzheimer's disease. Which comes first: The chicken or the egg? Antioxidants 10 (9), 1479. doi:10.3390/antiox10091479

PubMed Abstract | CrossRef Full Text | Google Scholar

Tan, F. H. P., and Azzam, G. (2017). Drosophila melanogaster: Deciphering alzheimer's disease. Malays. J. Med. Sci. MJMS 24 (2), 6–20. doi:10.21315/mjms2017.24.2.2

PubMed Abstract | CrossRef Full Text | Google Scholar

Téfit, M. A., and Leulier, F. (2017). Lactobacillus plantarum favors the early emergence of fit and fertile adult Drosophila upon chronic undernutrition. J. Exp. Biol. 220 (5), 900–907. doi:10.1242/jeb.151522

PubMed Abstract | CrossRef Full Text | Google Scholar

Tenreiro, P. A., Penacho Lázaro, A. M., Celda, A. R., Fernández, F. M., Mateo, G. C., and Hernández, D. A. (2013). Dietary treatment for X-linked adrenoleukodystrophy: Is “Lorenzo's oil” useful? Endocrinol. Nutr. (English) 60 (1), 37–39. doi:10.1016/j.endonu.2012.01.011

CrossRef Full Text | Google Scholar

Thau, L., Reddy, V., and Singh, P. (2022). Anatomy, central nervous system. StatPearls, 1–8. Available at: https://www.ncbi.nlm.nih.gov/books/NBK542179/.

Google Scholar

Thompson, P. M., Hayashi, K. M., de Zubicaray, G., Janke, A. L., Rose, S. E., Semple, J., et al. (2003). Dynamics of gray matter loss in Alzheimer's disease. J. Neurosci. 23 (3), 994–1005. doi:10.1523/JNEUROSCI.23-03-00994.2003

PubMed Abstract | CrossRef Full Text | Google Scholar

Tosti, V., Bertozzi, B., and Fontana, L. (2018). Health benefits of the mediterranean diet: Metabolic and molecular mechanisms. J. Gerontol. 73 (3), 318–326. doi:10.1093/gerona/glx227

PubMed Abstract | CrossRef Full Text | Google Scholar

Tracy, T. E., Madero-Pérez, J., Swaney, D. L., Chang, T. S., Moritz, M., Konrad, C., et al. (2022). Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration. Cell 185 (4), 712–728.e14. doi:10.1016/j.cell.2021.12.041

PubMed Abstract | CrossRef Full Text | Google Scholar

Trinder, M., Daisley, B. A., Dube, J. S., and Reid, G. (2017). Drosophila melanogaster as a high-throughput model for host-microbiota interactions. Front. Microbiol. 8, 751–758. doi:10.3389/fmicb.2017.00751

PubMed Abstract | CrossRef Full Text | Google Scholar

Tsigos, C., and Chrousos, G. P. (2002). Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J. Psychosom. Res. 53 (4), 865–871. doi:10.1016/s0022-3999(02)00429-4

PubMed Abstract | CrossRef Full Text | Google Scholar

Turcano, P., Stang, C. D., Bower, J. H., Ahlskog, J. E., Boeve, B. F., Mielke, M. M., et al. (2020). Levodopa-induced dyskinesia in dementia with Lewy bodies and Parkinson disease with dementia. Neurol. Clin. Pract. 10 (2), 156–161. doi:10.1212/CPJ.0000000000000703

PubMed Abstract | CrossRef Full Text | Google Scholar

Uemura, N., Yagi, H., Uemura, M. T., Hatanaka, Y., Yamakado, H., and Takahashi, R. (2018). Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve. Mol. Neurodegener. 13 (1), 21. doi:10.1186/s13024-018-0257-5

PubMed Abstract | CrossRef Full Text | Google Scholar

Van Ginneken, C., Schäfer, K. H., Van Dam, D., Huygelen, V., and De Deyn, P. P. (2011). Morphological changes in the enteric nervous system of aging and APP23 transgenic mice. Brain Res. 1378, 43–53. doi:10.1016/j.brainres.2011.01.030

PubMed Abstract | CrossRef Full Text | Google Scholar

Vandamme, T. F. (2014). Use of rodents as models of human diseases. J. Pharm. Bioallied Sci. 6 (1), 2–9. doi:10.4103/0975-7406.124301

PubMed Abstract | CrossRef Full Text | Google Scholar

Vandvik, P. O., Wilhelmsen, I., Ihlebaek, C., and Farup, P. G. (2004). Comorbidity of irritable bowel syndrome in general practice: A striking feature with clinical implications. APandT 20 (10), 1195–1203. doi:10.1111/j.1365-2036.2004.02250.x

PubMed Abstract | CrossRef Full Text | Google Scholar

Varatharaj, A., and Galea, I. (2017). The blood-brain barrier in systemic inflammation. Brain, Behav. Immun. 60, 1–12. doi:10.1016/j.bbi.2016.03.010

PubMed Abstract | CrossRef Full Text | Google Scholar

Venkat, P., Chopp, M., and Chen, J. (2015). Models and mechanisms of vascular dementia. Exp. Neurol. 272, 97–108. doi:10.1016/j.expneurol.2015.05.006

PubMed Abstract | CrossRef Full Text | Google Scholar

Vidal-Martínez, G., Vargas-Medrano, J., Gil-Tommee, C., Medina, D., Garza, N. T., Yang, B., et al. (2016). FTY720/Fingolimod reduces synucleinopathy and improves gut motility in A53T mice: Contributions of pro-brain-derived neurotrophic factor (PRO-BDNF) and mature BDNF. J biolog chem 291 (39), 20811–20821. doi:10.1074/jbc.M116.744029

CrossRef Full Text | Google Scholar

Villemagne, V. L., Pike, K. E., Darby, D., Maruff, P., Savage, G., Ng, S., et al. (2008). Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46 (6), 1688–1697. doi:10.1016/j.neuropsychologia.2008.02.008

PubMed Abstract | CrossRef Full Text | Google Scholar

Virmani, A., Pinto, L., Binienda, Z., and Ali, S. (2013). Food, nutrigenomics, and neurodegeneration - neuroprotection by what you eat. Mol. Neurobiol. 48 (2), 353–362. doi:10.1007/s12035-013-8498-3

PubMed Abstract | CrossRef Full Text | Google Scholar

von der Kammer, H., Hanes, J., Klaudiny, J., and Scheit, K. H. (1994). A human amyloid precursor-like protein is highly homologous to a mouse sequence-specific DNA-binding protein. DNA Cell Biol. 13 (11), 1137–1143. doi:10.1089/dna.1994.13.1137

PubMed Abstract | CrossRef Full Text | Google Scholar

von Frieling, J., Faisal, M. N., Sporn, F., Pfefferkorn, R., Nolte, S. S., Sommer, F., et al. (2020). A high-fat diet induces a microbiota-dependent increase in stem cell activity in the Drosophila intestine. PLoS Genet. 16 (5), e1008789. doi:10.1371/journal.pgen.1008789

PubMed Abstract | CrossRef Full Text | Google Scholar

Vossius, J. P., Janvin, C., and Aarsland, D. (2011). The economic impact of cognitive impairment in Parkinson’s disease. Mov. Disord. 26 (8), 1541–1544. doi:10.1002/mds.23661

PubMed Abstract | CrossRef Full Text | Google Scholar

Wagner, J. M., Sichler, M. E., Schleicher, E. M., Franke, T. N., Irwin, C., Löw, M. J., et al. (2019). Analysis of motor function in the tg4-42 mouse model of alzheimer's disease. Front. Behav. Neurosci. 13, 107. doi:10.3389/fnbeh.2019.00107

PubMed Abstract | CrossRef Full Text | Google Scholar

Wakade, C., Chong, R., Seamon, M., Purohit, S., Giri, B., and Morgan, J. C. (2021). Low-dose niacin supplementation improves motor function in us veterans with Parkinson's disease: A single-center, randomized, placebo-controlled trial. Biomedicines 9 (12), 1881. doi:10.3390/biomedicines9121881

PubMed Abstract | CrossRef Full Text | Google Scholar

Walker, L. C. (2020). Aβ plaques. Free Neuropathol. 1, 31. doi:10.17879/freeneuropathology-2020-3025

PubMed Abstract | CrossRef Full Text | Google Scholar

Wang, G., Huang, Y., Chen, W., Chen, S., Wang, Y., Xiao, Q., et al. (2016). Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson’s disease. Park. Relat. Disord. 24, 89–94. doi:10.1016/j.parkreldis.2015.12.018

PubMed Abstract | CrossRef Full Text | Google Scholar

Wang, Y., Pan, Y., and Li, H. (2020). What is brain health and why is it important? BMJ 371, m3683–m3687. doi:10.1136/bmj.m3683

PubMed Abstract | CrossRef Full Text | Google Scholar

Watts, J. C., Condello, C., Stöhr, J., Oehler, A., Lee, J., DeArmond, S. J., et al. (2014). Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients. Proc. Natl. Acad. Sci. U. S. A. 111 (28), 10323–10328. doi:10.1073/pnas.1408900111

PubMed Abstract | CrossRef Full Text | Google Scholar

Waxenbaum, J. A., Reddy, V., and Varacallo, M. (2022). Anatomy, autonomic nervous system. StatPearls. Available at: https://www.ncbi.nlm.nih.gov/books/NBK539845/.

Google Scholar

Weintraub, C. C. L., and Horn, S. (2008). Parkinson’s disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. Am. J. Manag. Care 14 (1), S40–S48.

PubMed Abstract | Google Scholar

Williams, J. M., Duckworth, C. A., Watson, A. J., Frey, M. R., Miguel, J. C., Burkitt, M. D., et al. (2013). A mouse model of pathological small intestinal epithelial cell apoptosis and shedding induced by systemic administration of lipopolysaccharide. Dis. Mod. Mech. 6 (6), 1388–1399. doi:10.1242/dmm.013284

PubMed Abstract | CrossRef Full Text | Google Scholar

Winiarska-Mieczan, A., Baranowska-Wójcik, E., Kwiecień, M., Grela, E. R., Szwajgier, D., Kwiatkowska, K., et al. (2020). The role of dietary antioxidants in the pathogenesis of neurodegenerative diseases and their impact on cerebral oxidoreductive balance. Nutrients 12 (2), 435. doi:10.3390/nu12020435

PubMed Abstract | CrossRef Full Text | Google Scholar

Wittmann, C. W., Wszolek, M. F., Shulman, J. M., Salvaterra, P. M., Lewis, J., Hutton, M., et al. (2001). Tauopathy in Drosophila: Neurodegeneration without neurofibrillary tangles. Science 293 (5530), 711–714. doi:10.1126/science.1062382

PubMed Abstract | CrossRef Full Text | Google Scholar

Wong, W. (2020). Economic burden of Alzheimer disease and managed care considerations. Am. J. Manag. Care 26 (8), S177–S183. doi:10.37765/ajmc.2020.88482

PubMed Abstract | CrossRef Full Text | Google Scholar

Woods, S. C., Seeley, R. J., Porte, D., and Schwartz, M. W. (1998). Signals that regulate food intake and energy homeostasis. Science 280 (5368), 1378–1383. doi:10.1126/science.280.5368.1378

PubMed Abstract | CrossRef Full Text | Google Scholar

World Health Organization (2022). Dementia. Retrieved form: https://www.who.int/news-room/fact-sheets/detail/dementia.

Google Scholar

Xiao, L., Feng, Q., Liang, S., Sonne, S. B., Xia, Z., Qiu, X., et al. (2015). A catalog of the mouse gut metagenome. Nat. Biotechnol. 33 (10), 1103–1108. doi:10.1038/nbt.3353

PubMed Abstract | CrossRef Full Text | Google Scholar

Xie, A., Gao, J., Xu, L., and Meng, D. (2014). Shared mechanisms of neurodegeneration in alzheimer’s disease and Parkinson’s disease. Biomed. Res. Int. 2014, 648740. doi:10.1155/2014/648740

PubMed Abstract | CrossRef Full Text | Google Scholar

Xiong, Y., and Yu, J. (2018). Modeling Parkinson's disease in Drosophila: What have we learned for dominant traits? Front. neurology 9, 228. doi:10.3389/fneur.2018.00228

CrossRef Full Text | Google Scholar

Yamaguchi, H., Yamazaki, T., Ishiguro, K., Shoji, M., Nakazato, Y., and Hirai, S. (1992). Ultrastructural localization of Alzheimer amyloid beta/A4 protein precursor in the cytoplasm of neurons and senile plaque-associated astrocytes. Acta neuropathol. 85 (1), 15–22. doi:10.1007/BF00304629

PubMed Abstract | CrossRef Full Text | Google Scholar

Yang, W., Hamilton, J. L., Kopil, C., Beck, J. C., Tanner, C. M., Albin, R. L., et al. (2020). Current and projected future economic burden of Parkinson's disease in the U.S. NPJ Parkinson's Dis. 6, 15. doi:10.1038/s41531-020-0117-1

PubMed Abstract | CrossRef Full Text | Google Scholar

Yoo, H. S., Lee, S., Chung, S. J., Lee, Y. H., Lee, P. H., Sohn, Y. H., et al. (2020). Dopaminergic depletion, β-amyloid burden, and cognition in Lewy body disease. Ann. Neurol. 87 (5), 739–750. doi:10.1002/ana.25707

PubMed Abstract | CrossRef Full Text | Google Scholar

Zeighami, Y., Ulla, M., Iturria-Medina, Y., Dadar, M., Zhang, Y., Larcher, K. M., et al. (2015). Network structure of brain atrophy in de novo Parkinson's disease. eLife 4, e08440. doi:10.7554/eLife.08440

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhang, R., Miller, R. G., Gascon, R., Champion, S., Katz, J., Lancero, M., et al. (2009). Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). J. Neuroimmunol. 206 (1-2), 121–124. doi:10.1016/j.jneuroim.2008.09.017

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhang, X., Fu, Z., Meng, L., He, M., and Zhang, Z. (2018). The early events that initiate β-amyloid aggregation in alzheimer's disease. Front. aging Neurosci. 10, 359. doi:10.3389/fnagi.2018.00359

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhao, X., and Bhattacharyya, A. (2018). Human models are needed for studying human neurodevelopmental disorders. Am. J. Hum. Gen. 103 (6), 829–857. doi:10.1016/j.ajhg.2018.10.009

CrossRef Full Text | Google Scholar

Zhao, Y., Dua, P., and Lukiw, W. J. (2015). Microbial sources of amyloid and relevance to amyloidogenesis and alzheimer's disease (AD). J. Alzheimer Dis. Park. 5 (1), 177. doi:10.4172/2161-0460.1000177

CrossRef Full Text | Google Scholar

Zhao, Y., Jaber, V., and Lukiw, W. J. (2017). Secretory products of the human GI tract microbiome and their potential impact on alzheimer's disease (AD): Detection of lipopolysaccharide (LPS) in AD Hippocampus. Front. Cell Infect. Microbiol. 7, 318. doi:10.3389/fcimb.2017.00318

PubMed Abstract | CrossRef Full Text | Google Scholar

Zheng, J. C., and Chen, S. (2022). Translational Neurodegeneration in the era of fast growing international brain research. Transl. Neurodegener. 11 (1), 1–11. doi:10.1186/s40035-021-00276-9

PubMed Abstract | CrossRef Full Text | Google Scholar

Zheng, H., Jiang, M., Trumbauer, M. E., Sirinathsinghji, D. J. S., Hopkins, R., Smith, D. W., et al. (1995). beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 81 (4), 525–531. doi:10.1016/0092-8674(95)90073-X

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhou, Y., Smith, D., Leong, B. J., Brännström, K., Almqvist, F., and Chapman, M. R. (2012). Promiscuous cross-seeding between bacterial amyloids promotes interspecies biofilms. J. Biol. Chem. 287 (42), 35092–35103. doi:10.1074/jbc.M112.383737

PubMed Abstract | CrossRef Full Text | Google Scholar